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ABSTRACT 
HIV may form reservoirs in anatomical compartments and evolve a quasispecies in order to 
survive under selective pressures such as antiretroviral drugs. Lymph nodes and lymphoid tissue 
- critical sites for reservoir formation - are environments conducive to cell-to-cell spread, an
efficient mode of HIV transmission. Cell-to-cell spread can lead to multiple infections per cell
which in turn profoundly changes how the virus responds to selective pressure.
In this thesis, my goal was to understand the consequences of multiple infections per cell on how 
the infection responds to and evolves in the face of inhibitors. The specific aims were to: (1) model 
and experimentally examine the effect of attenuating cell-to-cell spread by using antiretrovirals 
(ARVs) on infected cell viability; (2) test whether a stable quasispecies can be formed  and 
maintained by complementation– a process where virions derived from different HIV genotypes 
infecting the same cell share components; (3) test the feasibility of new single-cell RNA-Seq 
methodology that can be applied to quantify the frequency of multiply infected cells in vivo.  
These studies showed that: (1) partially attenuating infection involving multiple virions per cell with 
drug resulted in an increase in the number of live infected cells in both cell line and lymph nodes 
at suboptimal drug strengths. The increase in live infected cells was a result of fewer HIV DNA 
copies per cell, relative to no drug; (2) under the selective pressure of efavirenz (EFV), when 
drug-resistant and drug sensitive HIV co-infect the same cell during drug resistant evolution, 
complementation takes place, driving the formation and maintenance of a quasispecies; (3) Novel 
single-cell RNA-Seq approaches are feasible to quantify the number of cells that are multiply 
infected in vivo. Inhibiting mechanisms such as cell-to-cell spread may therefore reduce infection 
in the face of ARVs and limit viral diversity and hence the ability of HIV to evolve resistance.  
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INTRODUCTION 1 
Both the development of HIV anatomical reservoirs and the generation of a robust HIV 2 
quasispecies are constraints to a successful cure. Critical anatomical reservoirs are lymph nodes 3 
and lymphoid tissue. These environments are conducive to infection due to the presence of 4 
infectible cells 1-3 and the lack of flow of cells which enables cell-to-cell-spread of HIV 4-15. 5 
6 
Although cell-to-cell spread is an efficient means of transmitting HIV and assists in the 7 
development of a reservoir, it causes CD4+ T cell death 16,17. Cell death occurs by several 8 
mechanisms, which are either directly or indirectly mediated by HIV infection. Accumulation of 9 
incompletely reverse transcribed HIV transcripts is sensed by interferon-γ–inducible protein 16 17 10 
and leads to pyroptotic death of incompletely infected cells by initiating a cellular defense program 11 
involving the activation of caspase 1 16,17,20. HIV proteins Tat and Env have also been shown to 12 
lead to cell death of infected cells through CD95 mediated apoptosis following T cell activation 21-13 
23.  Finally, double strand breaks in the host DNA caused by integration of the reverse transcribed14 
virus results in cell death by the DNA-PK mediated activation of the p53 response 18. 15 
16 
Cell-to-cell spread is thought to be the main cause of multiple infections per cell 9. Several studies 17 
have shown that multiple infections in lymph nodes cells is frequent 24-26 while another study 18 
demonstrated that this is not the case  30. Multiple infection attempts may be enough to lead to 19 
cell death. Hence, multiply infected cells may die before being detected. One consequence of HIV 20 
mediated death may be that attenuation of cell-to-cell spread with ARVs may increase the number 21 
of live infected cells. Indeed, it has been suggested that more attenuated HIV strains result in 22 
more successful infections in terms of the ability of the virus to replicate in the infected individual 23 
31-35. An increase in the number of live infected cells as a result of attenuation of cell-to-cell spread24 
by ARVs may not necessarily contribute to a bigger reservoir but may assist to the establishment 25 
of a reservoir after therapy initiation. Recently it was shown in outgrowth assays, 60 to 100% of 26 
the viruses from patients on prolonged ARV treatment were genetically related to virus circulating 27 
prior to treatment and only 0 to 22% were related to virus circulating during treatment, suggesting 28 
ART contribute to reservoir formation 36. 29 
30 
In addition to the number of infected cells in the face of drug, multiple infections per cell may 31 
influence HIV evolution. HIV evolves and exists as multiple genotypes in a single infected 32 
individual, referred to as a quasispecies. Evidence of an HIV quasispecies within a host comes 33 
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from: (1) ENV diversity, which allows HIV to evade immune pressures by escaping neutralizing 34 
antibodies 37,38; (2) co-existence of drug resistant and drug sensitive HIV variants in treatment 35 
naïve patients 39-42; (3) co-existence of drug resistant and drug sensitive HIV genomes in patients 36 
on antiretroviral therapy 43-45.  37 
 38 
Due to the errors in reverse transcription, HIV replication generates a quasispecies where variants 39 
are at low frequencies around the main viral sequence 46-48. However, how a stable quasispecies 40 
with variants at high frequencies is maintained is unclear. One possibility is that different 41 
anatomical environments apply different selective pressures, therefore leading to a diverse viral 42 
pool 49,50. One mechanism to create a quasispecies that does not rely on the assumption of 43 
different environments is complementation 51,52. In complementation, a virus of genotype 1 may 44 
contain proteins from virus of genotype 2 and vice versa. If one of the genotypes has a fitness 45 
cost relative to the other, the difference in fitness will be masked. Given that cells in lymph nodes 46 
are conducive to cell-to-cell spread and that this mode is thought to be the main cause of high 47 
multiplicity of infection (MOI), it may be possible that multiple genetic variants from contacts with 48 
different infected cells infect the same cell and “mix” their viral components frequently enough to 49 
sustain and maintain an HIV quasispecies under selective pressure.   50 
 51 
The degree to which multiple successful infections occur per cell has been disputed. One 52 
challenge with quantifying the number of infections per cell is the limitations of established assays, 53 
since partial efficiency of detection would translate to decreased HIV copy number per cell. 54 
Therefore, multiple infections are extremely dependent on the sensitivity of the assay used. 55 
However, new technologies such as single-cell RNA Seq, which are designed to detect gene 56 
transcripts on the level of the individual cell, may offer a new perspective on the detection problem.  57 
 58 
The aims of the studies below was to examine the effects of multiple infections per cell on 59 
HIV infection and evolution in presence of selective pressure.  60 
 61 
Aim1: Determine the effects of multiple infection of cells on cell death.  62 
Aim2: Determine the effects of multiply infected cells on the development of a quasispecies 63 
during evolution of drug resistance, via the mechanism of complementation.  64 
Aim3: Review and test the feasibility to quantify the frequency of multiply infected cells in vivo65 
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CHAPTER 1: 
Literature Review 
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1.1 Origin of HIV 66 
Human immunodeficiency virus (HIV) is a lentivirus as well as a subgroup of retroviruses. HIV 67 
causes acquired immunodeficiency syndrome (AIDS). A common property of lentiviruses is that 68 
they are transmitted as single-stranded positive-sense enveloped viruses. HIV is a parasitic virus 69 
and therefore requires a host cell in order to replicate and survive. HIV can be transmitted from 70 
person to person via blood, pre-ejaculate, semen and vaginal fluids. Non-sexual transmission 71 
from mother to child can occur during pregnancy, childbirth or breast milk. 72 
HIV is believed to have originated in non-human primates in West-central Africa and transferred 73 
to humans in the early 20th century 53.  HIV is closely related to simian immunodeficiency virus 74 
(SIV). SIV has evolved many strains, classified by their natural host species. Many of the SIV 75 
strains have had a long history with their host. SIV hosts have adapted in the presence of the 76 
virus. Together with the genetic makeup of the virus, SIV has resulted in mild immune responses 77 
and SIV AIDS does not develop in the host 54. Two types of HIV have been characterized, HIV-1 78 
and HIV-2. HIV-1 is most widespread around the world, with HIV-2 being less prevalent and less 79 
pathogenic. HIV-2 is mostly confined to West Africa 55.  Three different groups of HIV-1 have been 80 
identified based on the difference in the envelope protein. These groups include, M, N and O 56. 81 
Group M is the most prevalent and is subdivided into eight different subtypes or clades. The 82 
clades are based on the whole genome and are geographically distinct. Most HIV infections in 83 
Africa are caused by Clade C subtype 56. 84 
1.2 Structure and Life cycle of HIV 85 
86 
The HIV genome is composed of nines genes; Gag, Pol Env, Tat, Rev, Nef, Vif, Vpr and Vpu 87 
(Figure 1). The genome is flanked by a 5’ and 3’ long terminal repeat (LTR). Gag, Pol and Env 88 
contain sequences required to make enzymes and structural proteins for the new virus particle 57. 89 
Specifically, the Gag gene encodes for four smaller proteins, namely; matrix, capsid (p24), 90 
nucleocapsid and p6 57. Pol encodes for the viral protease, integrase and reverse transcriptase 91 
(RT) 57. Env encodes for the glycoprotein gp160, which is a precursor to gp120 and gp41 57. Tat, 92 
Rev, Nef, Vif, Vpr and Vpu are regulatory genes that code for proteins that control the ability of 93 
HIV to infect a cell, import in to the host nucleus and produce new copies of virus (Figure 1). 94 
95 
Each HIV virion is composed of two positive sense single stranded RNAs that codes the viruses’ 96 
nine genes (Figure 2). The RNAs are bound to the nucleocapsid (not shown in Figure 2). In turn, 97 
the nucleocapsid is enclosed by an outer p24 capsid. Enzymes required for the development of 98 
a new virion, such as RT, proteases and integrases are also enclosed within the capsid. The 99 
Page 14 of Thesis
capsid is surrounded by a viral envelope, which is composed of a lipid bilayer taken from the host 100 
cell when it buds off it. The viral envelope consists of an Env-glycoprotein complex, which includes 101 
the gp160 spike (gp120 and gp41). 102 
103 
The first step in the HIV life cycle is entry into the host cell. This is mediated through the interaction 104 
of HIV gp120 and CD4 on the target cell membrane 58,59. The interaction induces a conformational 105 
change in the envelope protein that in turn allows the binding of the virion to chemokine co-106 
receptors on the surface of the host cell. Macrophage tropic (M-tropic) strains of HIV, generally 107 
called R5 HIV, use the CCR5 chemokine co-receptor, whereas T cell tropic (T tropic) strains of 108 
HIV, or X4 HIV,  bind CXCR4 60. X4 strains are frequently found during later stages of disease60. 109 
HIV can also enter a host cell via a pH-independent endocytosis 61 (Figure 2). 110 
111 
The stable interaction between HIV and host cell surface allows for gp41 to penetrate the cell 112 
membrane, causing the virus and cell membrane close together and subsequent fusion of the 113 
membranes 62. The HIV capsid is released into the cell, where the capsid is uncoated and viral 114 
proteins, (RT, integrase, proteases) as well as viral double stranded RNA is released into the 115 
cytoplasm. RT contains RNA-dependent DNA polymerase activity, DNA-dependent DNA 116 
polymerase activity and RNase H activity 63,64. RT reverse transcribes a single positive sense viral 117 
RNA genome into a double stranded DNA copy 63,64. The RNase H is used to remove the original 118 
RNA viral template from the first DNA strand. RT, together with the copy DNA, integrase and Vpr, 119 
form a pre-integration complex (PIC) 65. The PIC is then transported to the nucleus. Vpr has been 120 
Figure 1. HIV genome structure. HIV genome consists of nine genes; Gag, Pol Env, Tat, Rev, Nef, Vif, Vpr and 
Vpu. The viral genomes are flanked by a 5’ and 3’ LTRs. Gag, Pol and Env contain information needed to make 
structural proteins and enzymes for the new virus particle. Tat, Rev, Nef, Vif, Vpr and Vpu are regulatory genes the 
code for proteins that control the ability of HIV to infect a cell, import in to the host nucleus and produce new copies 
of virus (functions shown above).  
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implicated in mediating the nuclear import of PIC 66. 121 
122 
Integration of the viral copy DNA is facilitated by integrase. The integrated viral copy DNA, namely 123 
proviral DNA, can lead to transcriptionally active or latent forms of infection. In the host genome, 124 
the LTRs function as eukaryotic transcriptional elements, containing downstream and upstream 125 
transcriptional promoter elements 67. These elements help position the RNA polymerase II 67. This 126 
in turn, leads to transcription of the HIV genome. Some of the transcribed RNA created undergoes 127 
splicing to produce messenger RNA (mRNA). The mRNA is transported into the cytoplasm where 128 
it is translated into proteins. The translated regulatory protein, Rev, binds to the Rev response 129 
element (RRE), part of the second intron of HIV, in the nucleus 68. This binding facilitates the 130 
export of unspliced and incompletely spliced transcribed viral RNA from the nucleus to the 131 
cytoplasm 68. Some of the full-length transcribed viral RNAs function as new copies of the virus 132 
genome, while multiply spliced transcripts encode Nef, Tat and Rev. Other singly spliced or 133 
unspliced viral transcripts encode polyproteins, such as gp160 (later cleaved in gp120 and gp41), 134 
Gag and Gag-Pol polyproteins or precursor 69. 135 
136 
The cleavage products of gp160, gp120 and gp41, are transported to the plasma membrane of 137 
the infected cell. The Gag and Gag-Pol polyproteins also become associated with the plasma 138 
membrane of the infected cell and along with the HIV transcribed RNA and Vpr, form a virion that 139 
begins to bud. On average about 100 molecules of Gag-Pol and 1500 Gag polyproteins are 140 
packaged in the assembled genome 70. The budded virion is considered immature as the Gag 141 
and Gag-Pol polyproteins still require cleavage. Cleavage of the Gag-Pol precursor results in the 142 
production of protease, integrase, RT. Cleavage of Gag results in the capsid (p24) and 143 
nucleocapsid. The cleavage is mediated by HIV protease. 144 
145 
Mature virions can infect new cells. Two known modes of infections of host cells have been 146 
described. These include cell-free and cell-to-cell mode of infection. Below, I will describe both 147 
modes as well as the implications of both. 148 
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1.3 Cell-to-cell infection 149 
 150 
Cell-to-cell is a mode of infection, only described for enveloped viruses, whereby virus is spread 151 
from an infected cell to an uninfected target cell in close proximity. This is unlike a cell-free 152 
infection where free floating virus in the extracellular milieu infects a cell (Figure 3A). In cell-to-153 
cell spread, this contact-dependent mode of transmission involves the formation of either a 154 
virological synapse10,71,72 or an infectious synapse 73 between immune cells.  Virological synapses 155 
are formed by HIV infected cells, where virus can bud from the plasma membrane and infect a 156 
target cell that is polarized and in close contact with the infected cell. Infectious synapses are 157 
formed by uninfected cells that capture free HIV on its surface and uninfected target cell in that 158 
are in close proximity. Both types of synapses enable a stable polarization after contact with other 159 
cells which are generally immobile in the tissue 9-11.  160 
 161 
The virological synapse formed during cell-to-cell infection is initiated by the binding the HIV 162 
envelope protein (ENV), on the surface of an infected cell, with CD4 on the surface of an 163 
uninfected T cell 10 (Figure 3B). After stable adhesion is established, the viral protein Gag is 164 
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Figure 2. Life cycle of HIV. HIV enter a cell through either ENV and host cell receptor binding and subsequent 
fusion or through endocytosis. HIV capsid is released into the cell where viral RNA is reverse transcribed into viral 
DNA. Viral DNA is integrated into the host genome and following transcription, splicing and translation, new HIV 
proteins and viral RNA are produced that are then assembled at the host cell membrane and released from the host 
cell via budding. 
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recruited to the cell contact in an actin-dependent manner 10. Actin rearrangements  165 
 
 
 
appear to be critical for the formation of a virological synapse on the infected donor cell side, 166 
where filamentous actin accumulates at the site of adhesion 74. Several other adhesion molecules 167 
such as intercellular adhesion molecule 1 (ICAM-1), ICAM-3 and leukocyte function-associated 168 
antigen 1 (LFA-1) can promote the formation of a virological synapse 75-77. The CD4-ENV 169 
interaction, along with the other adhesion molecules results in a stable binding that subsequently 170 
leads to the production of virus at the site of the cell-to-cell contact 9,11. It is possible for one 171 
infected cell T cell to assemble multiple cell-to-cell contacts or virological synapses with several 172 
target simultaneously (polysynapse) 76. 173 
 174 
The most well characterized infectious synapse with an antigen presenting donor are dendritic 175 
cells (DCs). DCs survey mucosal tissues and transport HIV to secondary lymphoid tissues 78,79. 176 
In the lymphoid tissues, DCs can form an infectious synapse with the CD4+ T cells 73,80. DC-177 
Figure 3. Modes of entry of HIV into targets cells. (A) Cell-free virus released into the extracellular milieu bind 
CD4 on the target cell surface via HIV ENV gp120. (B) Virological synapse and (C) Infectious synapses for different 
cell types. (B) Infected CD4 T cell binds to an uninfected T cell through engagement of HIV ENV. Adhesion 
molecules LFA-1 and ICAM-1 also facilitate in cell-to-cell contact. (C) Dendritic cell to T cell or CD4+ expressing cell 
involves capture of HIV through DC-SIGN and CD-169 for either internalisation into the DC or transient surface 
attachment until a cell-to-cell synapse has been made. Adhesion molecules LFA-1 and ICAM-1 facilitate in synapse 
formation. (D) Macrophage to T cell synapse-like interface. Macrophages can internalize HIV through CD4 and 
CD169 binding. HIV can be spread directly to uninfected T cells across a synapse-like interface (adapted from Law 
et al., 2016). 
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specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), is a C-type lectin and 178 
mediates the capture and/or internalization of HIV, by interacting with gp120 81 (Figure 3C). Other 179 
molecules such as CD169, on the surface of DCs can also help capture HIV 82. Both LFA-1 and 180 
ICAM-1 adhesion molecules facilitate in the formation of the infectious synapse of a DC with an 181 
uninfected target cell 83. A infectious synapse-like interface can also be formed with macrophages 182 
84-86. Here, HIV is captured on the surface of macrophages and subsequently internalized for 183 
infection. The efficient capture is mediated by CD169/CD4 87 (Figure 3D).  184 
 185 
It is well known that HIV replicates rapidly in target cells co-cultured with infected cells than with 186 
cell-free virus inoculation 88-90. It has been demonstrated in an in vitro co-culture systems, where 187 
both cell-free and cell-to-cell HIV infection occured, cell-to-cell spread was the predominant mode 188 
of HIV dissemination 14.  The relative contribution of cell-to-cell spread via synapses is difficult to 189 
visualize in vivo and therefore difficult to quantify. Virus transmitted via cell-to-cell spread may 190 
overcome many of the barriers that the cell-free virus faces. Infected cells entering a new host 191 
can avoid mucosal epithelial barriers that would normally be impermeable to free virions. Virus 192 
spread by cell-to-cell transmission does not have to diffuse in the cellular milieu like cell-free virus 193 
90. This diffusion step can result in a progressive loss of infectivity for cell-free virus. HIV spreading 194 
directly from one cell to another cell can be more protected from the immune response that 195 
otherwise targets the virus. It has been shown that cell-associated virus exhibits greater 196 
resistance to neutralization by patient antisera as compared with a homologous cell-free viral 197 
challenge 89,91. Possible reasons for the reduced efficiency of neutralization by antibodies in 198 
patient sera may include the Env conformation on HIV infected cells, kinetic barriers or the 199 
multiplicity of HIV infection per cell 92.  With regards to the latter, it has been shown that cell-to-200 
cell spread leads to the transfer of a large amount of virus4,9,11,26,27,84,93-100, resulting in multiple 201 
infection attempts (discussed below). Sigal et al. (2011) showed that multiple virions transmitted 202 
per cell can increase the probability that at least one virion escapes antiretroviral therapy and in 203 
doing so, continues to infect.   204 
 205 
1.3.1 High multiplicity of infection 206 
 207 
An important feature of HIV cell-to-cell spread is the transfer of large amounts of virus per infection 208 
event from an infected cell to an uninfected target cell 4,9,11,26,27,84,93-100. Transmission electron 209 
micrographs (TEMs) depict many free virus particles in the space between the donor and target 210 
cells 11 (Figure 4). A study of the gut-associated lymphoid tissue (GALT) of HIV infected mice with 211 
humanized immune systems showed that the number of HIV virions in the intercellular pools in 212 
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the GALT region near the edge of a crypt ranged from 17 to 59 100. These HIV intercellular pools 213 
were seen as tight areas of free virus between cells and would require cell morphologies to 214 
change in order for virus to escape.  TEMs from another study do not show free viral particles in 215 
the synaptic space but rather nascent, crescent viral buds that are directly apposed to the target 216 
cell membrane 9. In either case, the large transfer of virus numbers is unique to cell-to-cell spread.  217 
 218 
It has been shown in lymphoid tissues that the majority of trapped HIV (estimated at 1.5 × 108 219 
copies of viral RNA per gram lymphoid tissues) exists on the surface of follicular dendritic cells 220 
(FDCs) in the germinal centers 101. FDCs can retain a high concentration of infectious HIV in close 221 
proximity to susceptible CD4+ T cells. Earlier work demonstrated that CD57+CD4+ T cells in 222 
germinal centers intimately interact with FDCs in direct cell-to-cell contact 102. More recent work 223 
has shown that T follicular helper cells - in direct contact with FDCs - are responsible for HIV 224 
replication in both viremic 103 and aviremic 104 HIV infected patients.  225 
 
 
 
  
 
A transfer of large amounts of virus during cell-to-cell spread increases the chances that cells will 226 
become multiply infected 27,93,98. Del Portillo et al. (2011) showed, using fluorescence in situ 227 
hybridization (FISH), that the average copy number of proviral genomes per cell in cell-to-cell 228 
spread in in vitro PBMC infections is ~2.5-fold higher than that in cell-free infection (Figure 5). 229 
Multiple infections per cell, as measured by the number of proviral DNA copies, occurs frequently 230 
in the lymph nodes 24 but with  lower rates (1-10%) in the peripheral blood 30,105. Meyerhans 231 
Figure 4. Transfer of large amounts of HIV from 
an infected cell to an uninfected cell at the site 
of a virological synapse. Infected Jurkat T cells 
were mixed with primary CD4+ T cells, fixed and 
embedded. Secretory organelles (endoplasmic 
reticulum, ER, not pseudocoloured), secretory 
lysosomes (SL, orange), Golgi (G, not 
pseudocoloured), mitochondria (m, green) and 
lipid bodies (LB, pale blue) and microtubule 
organizing centre – MTOC - (blue), towards the 
site of virus particle (vi, red) release in the HIV-1 
infected T cell (adapted from Jolly et al., 2011) 11.  
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Figure 6. HIV-infected splenocytes harbour many proviruses. (A), FISH image of HIV-1 proviruses in 
interphase nuclei and metaphase chromosomes from splenocytes. Green, integrated HIV genomes, or proviruses; 
Red, centromeric region of chromosome 12. (B), Frequency distribution of the number of HIV-1 proviral copies per 
infected cell (adapted from Jung et al., 2002) 24. 
 
showed in two studies that a majority of in vivo  infected splenocytes harbored a mean 3.2 proviral 232 
HIV copies/cell as detected by FISH (Figure 6A and B) 24 28. In contrast, Josefsson et al. (2011 233 
and 2013) showed that only ~ 5-7% of CD4+ T cells circulating the blood and peripheral lymphoid 234 
tissues carry more than 1 provirus. 235 
 
 
 
 
 
 
 
There are two possible explanations for the variations in the number of proviral HIV copies per 236 
cell. Firstly, different cell subsets are infected to different degrees. Recent work investigating 237 
markers associated with HIV latency in the face of antiretroviral therapy (ART) found that the 238 
average number of HIV DNA copies per cell in blood samples is greater than one in 3 out of 12 239 
individuals.  240 
 
Figure 5. Increased number of proviral copies 
in cell-to-cell spread compared to cell-free 
infection.  Distributions of nuclear HIV-1 proviral 
copies in an in vitro infection of CD4+ cells isolated 
from two different blood donors. Combined means 
± SEM are shown. Blood donor 1: cell-free mean 
= 1.11, n = 26; cell-to-cell mean = 3.72, n = 
25, P = 0.0003. Blood donor 2: cell-free mean = 
1.55, n = 20; cell-to-cell mean = 3.95, n = 20, P = 
0.0138. Combined blood donors: donor cell mean 
= 3.71, n = 45, cell-free mean = 1.30, n = 46, cell-
to-cell mean = 3.82, n = 45; P values are 
displayed. Significance was tested using the two-
tailed Mann-Whitney U test with an alpha level of 
0.05 (adapted from Del Portillo et al., 2011) 27.  
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Figure 7. The mode of HIV spread 
determines the type of cell death. Cell-free 
HIV particles result in productive infection 
and caspase 3 apoptosis in a small fraction 
of permissive lymphoid CD4+ T cells. Cell-
to-cell spread of HIV is required to deplete 
the non-permissive lymphoid CD4+ T cells, 
which represent 95% or more of the target 
cells in lymphoid tissues, via caspase 1-
dependent pyroptosis. Free HIV particles, 
even at high quantities, cannot trigger innate 
immune recognition and produce this form of 
cell death (adapted from Galloway et al., 
2015) 16. 
 
 
This occurred in the CD3+ positive, CD32a high CD4+ T cell subset 106. A second reason for the 241 
discrepancy in the results from the different studies is that multiply infected cells may die more 242 
frequently through cell-to-cell spread. 243 
 244 
1.3.2 Cell Death in cell-to-cell spread 245 
 246 
HIV infection is known to result in extensive T cell depletion in lymph node environments where 247 
the force of infection is high 16,17,20,107-109. The mode of HIV infection can determine the pathway 248 
for cell-death. Cell-free infection can lead to caspase 3 apoptosis in small fraction of permissive 249 
CD4+ T cells in the lymphoid tissue 16 (Figure 7). For the remaining less permissive targets, cell-250 
to-cell spread is required with the accumulation of incompletely reverse transcribed HIV 251 
transcripts being sensed by interferon-γ–inducible protein 16 (IFI16) 17, depleting cells via a 252 
caspase 1-depedent pyroptosis 16,17 (Figure 7).  253 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cooper et al. (2013) demonstrated that double strand breaks in the host DNA caused by 254 
integration of the reverse transcribed virus results in cell death (Figure 8A). The accumulation of 255 
unintegrated reverse transcripts as measured by the long terminal repeat (LTR) copy number has 256 
less of an effect of cell death (Figure 8A).  Furthermore, these authors showed cell death can be 257 
reduced by reducing the amount proviral integration and that cell death was a DNA-PK mediated 258 
activation of the p53 response (Figure 8B and C). Other mechanisms of T cell death may or may 259 
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Figure 8. Proviral DNA integration triggers cell death through DNA-PK mediated activation of p53 
during HIV infection. (A) Cell death and proviral DNA analyses of CD4+ lymphocytes infected with wild type 
HIV NL43 or with HIV NL43 D64V integrase mutant. (B) Western blot analysis showing phosphorylation of 
DNA-PK, p53 and H2AX following high MOI HIV infection with either wild type or mutant virus in primary CD4+ 
lymphocytes. (C) Cell death analysis gated on p24+ cells of primary CD4+ lymphocyte cultures either 
uninfected or infected with HIV-189.6 in the absence or presence of DNA-PK inhibitors NU7026 or NU7441 
for 7 days. Data in panels A and C are representative of at least two independent experiments done in 
triplicate. Error bars represent the standard deviation of the mean of cell death (adapted from Cooper et al., 
2013) 18. 
 
not be dependent on cell-to-cell infection. HIV proteins Tat and Env have also been shown to lead 260 
to cell death of infected cells through CD95 mediated apoptosis following T cell activation 21-23. 261 
Therefore, counterintuitively, HIV cell-to-cell spread, a much more efficient infection mechanism, 262 
may act to limit the number of infected cells by promoting cell-death. 263 
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Figure 9. Drug concentrations determine 
the relative fitness of the wild type and 
drug resistant virus. (A) As measured by the 
replication ratio (R0), the wild type (blue line) 
is most fit at low drug concentrations and 
dominates in the wild type growth window 
(WGW, grey area).  A drug resistant mutant 
(red line) is less fit than the wild type at low 
concentrations but more fit at higher drug 
concentrations, out-competing wild type in the 
mutant selection window (MSW, brown area). 
In the overlapping windows (orange area), 
both mutant and wild type can grow but with 
decreasing replication. At very high drug 
concentrations (green area), the replication 
ratio  of both wild type and mutant is <1 and 
the virus does not (adapted from Rosenbloom 
et al., 2012) 29. 
 
1.2.3. Evolving a quasispecies 264 
 265 
The evolution of a genetically diverse population of variants, or quasispecies, enables HIV to 266 
adapt and survive in ever changing environments. Evidence of an HIV quasispecies within a host 267 
includes: (1) ENV diversity, which has allowed for HIV to evade immune pressures by escaping 268 
neutralizing antibodies 37,38; (2) co-existence of drug resistant and drug sensitive HIV variants in 269 
treatment naïve patients 39-42; (3) co-existence of drug resistant and drug sensitive HIV genomes 270 
in patients on antiretroviral therapy 43-45. Whether the outgrowth of wildtype (drug sensitive) virus 271 
after antiretroviral therapy interruption is a result of the latter quasispecies formation is still to be 272 
determined.  273 
 274 
Predictions on when  drug resistant and drug sensitive variants arise are based on a current model 275 
which describes drug resistant mutants arising in the mutant selection window (MSW), where at 276 
higher drug concentrations, the relative fitness of the mutant is higher than that of the wildtype 277 
virus 29,110 (Figure 9). This model cannot adequately account for the generation and maintenance 278 
of an HIV quasispecies as a counter-force to drug resistant evolution, where less fit and more fit 279 
variants to stably co-exist.  280 
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Figure 10. HIV ENV sequence diversity from a single splenocyte. HIV ENV V1/V2 amino acid sequences from 
a single splenocyte compared to reference sequence. The sequences are grouped and coded by capital letters to 
the right.  Dots denote synonymous substitutions, while arrows correspond to recombination sites (adapted from 
Suspene et al., 2012) 28. 
 
Intracellular-cell selection of HIV in multiply infected cells introduces new evolutionary dynamics. 281 
Multiple infections per cell can result in the co-infection of genetically distinct HIV variants. Co-282 
infection of genetically distinct HIV variants has been well documented 24,28,30,95,111-113. For 283 
example, as depicted in Figure 10, a single splenocyte from an HIV infected individual can harbour 284 
multiple variants of the ENV region.  285 
 286 
One mechanism to create a quasispecies that does not rely on the assumption of different 287 
environments is complementation, also called phenotypic mixing 51,52. In this mechanism, co-288 
infection and viral protein expression from two different viral genotypes in the same cell results in 289 
sharing of viral components. This is distinct from recombination, where two viral genomes co-290 
packaged in the same cell recombine to form a new genome 114. In complementation, a virus of 291 
genotype 1 may contain proteins from virus of genotype 2 and vice versa. If one of the genotypes 292 
has a fitness cost relative to the other, the difference in fitness will be masked 115. This process 293 
has been shown to operate in viruses 116,117 including HIV 112,113. There is no known mechanism 294 
which prevents one HIV strain packaging components such as reverse transcriptase from another 295 
HIV strain if both strains are in the same cell since RT molecules mix in the cell cytoplasm 118. 296 
The first step in determining whether complementation is relevant, particularly in patients on 297 
antiretroviral therapy or harboring some level of drug resistant mutations, is quantifying how 298 
frequent multiple variants infect the same cell in vivo. This would include using novel, sensitive 299 
single cell techniques. 300 
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1.4 Single cell RNA-Seq methods to determine the number of HIV infections per cell 301 
 302 
A novel approach to define the HIV cellular reservoir and associated sequences at the level of 303 
the single infected cell is the emerging technology of single cell RNA-Seq. This enables analysis 304 
of single-cell transcriptomes to discover cell type/state 119, and can also be used to detect HIV 305 
transcripts in individual cells. For example, Seq-Well is a microwell-based platform that enables 306 
high-throughput single cell RNA-Seq using ~86,000 subnanoliter wells pre-loaded with barcoded 307 
mRNA capture beads. Each cell is captured with a single bead in a single well using gravity.  308 
 
 
 
 
 
 
The wells are then sealed using a semi-permeable membrane, cells are lysed within the array, 309 
and cellular mRNAs are captured on barcoded beads (Figure 11). Reverse transcription, library 310 
preparation and paired-end sequencing is carried out 120-122. Seq-Well enables transcriptomic 311 
profiling of thousands of cells in parallel, with each cell profiled individually by applying unfixed 312 
cells in suspension to the microwell chip 123.  313 
 
Figure 11. Seq-Well workflow. Cells are obtained from tissues and processed to form a single-cell suspension. 
Barcoded mRNA capture beads are added to the surface of the microwell device, settling into wells by gravity, and 
then the single-cell suspension is applied. The device is sealed using a semi-permeable membrane that, upon addition 
of a chemical lysis buffer, confines cellular mRNAs within wells while allowing efficient buffer exchange. Liberated 
cellular transcripts hybridize to the bead-bound barcoded poly(dT) primers that contain a cell barcode (shared by all 
probes on the same bead but different between beads) and a unique molecular identifier (UMI) for each transcript 
molecule. After hybridization, the beads are removed from the array and bulk reverse transcription is performed to 
generate single-cell cDNAs attached to beads. Libraries are then made by whole transcriptome amplification (WTA) 
and sequenced. After, single-cell transcriptomes are assembled in silico using cell barcodes and UMIs. 
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In addition to Seq-Well, other single cell RNA-Seq approaches can be used to specifically detect 314 
and analyze the transcriptomes of HIV infected cells. These techniques sequence cells in a 96-315 
well format and therefore rely on enrichment strategies of HIV infected cells.  One such approach 316 
is using Fixed and Recovered Intact Single-cell RNA (FRISCR) 124 for HIV infected cells (Figure 317 
12). HIV infected cells can be enriched using intracellular anti-HIV Gag (p24) staining. With the 318 
FRISCR approach, fixed HIV infected cells are single cell sorted into a Proteinase K digestion 319 
buffer (PKD). Each cell in the well is lysed and the RNA is reverse crosslinked by heating. FRISCR 320 
has been successfully applied to radial glia cells of the human neocortex, yielding expression data 321 
similar to that of unfixed cells 124.  If direct detection of HIV is not possible, an alternative is single 322 
cell RNA-Seq of cell types enriched for HIV infection. Here, cells are sorted based of cell-surface 323 
markers rather than fixing and using intracellular staining. 324 
 
 
Figure 12. Steps in the FRSICR method. The first step of the process is to dissociate, fix, permeabilize and stain a 
population of cells. Cells are then single cell sorted based on staining markers. For HIV, this would be sorting on p24 
positive cells. Single cells are sorted into a Proteinase K digestion buffer. Each cell is lysed and the mRNA is reverse 
cross-linked by heating. The mRNA is purified using Oligo dT25 beads and the sample is then applied to RNA 
sequencing (adapted from Thomsen et al., 2016) 124. 
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Abstract HIV has been reported to be cytotoxic in vitro and in lymph node infection models.
Using a computational approach, we found that partial inhibition of transmissions of multiple
virions per cell could lead to increased numbers of live infected cells. If the number of viral DNA
copies remains above one after inhibition, then eliminating the surplus viral copies reduces cell
death. Using a cell line, we observed increased numbers of live infected cells when infection was
partially inhibited with the antiretroviral efavirenz or neutralizing antibody. We then used efavirenz
at concentrations reported in lymph nodes to inhibit lymph node infection by partially resistant HIV
mutants. We observed more live infected lymph node cells, but with fewer HIV DNA copies per
cell, relative to no drug. Hence, counterintuitively, limited attenuation of HIV transmission per cell
may increase live infected cell numbers in environments where the force of infection is high.
DOI: https://doi.org/10.7554/eLife.30134.001
Introduction
HIV infection is known to result in extensive T cell depletion in lymph node environments
(Sanchez et al., 2015), where infection is most robust (Brenchley et al., 2004; Doitsh et al., 2010;
Doitsh et al., 2014; Finkel et al., 1995; Galloway et al., 2015; Mattapallil et al., 2005). Depletion
of HIV infectable target cells, in addition to onset of immune control, is thought to account for the
decreased replication ratio of HIV from an initial peak in early infection (Bonhoeffer et al., 1997;
Nowak and May, 2000; Perelson, 2002; Phillips, 1996; Quin˜ones-Mateu and Arts, 2006;
Ribeiro et al., 2010; Wodarz and Levy, 2007). This is consistent with observations that individuals
are most infectious in the initial, acute stage of infection, where the target cell population is rela-
tively intact and produces high viral loads (Hollingsworth et al., 2008; Wawer et al., 2005).
T-cell death occurs by several mechanisms, which are either directly or indirectly mediated by HIV
infection. Accumulation of incompletely reverse transcribed HIV transcripts is sensed by interferon-
g–inducible protein 16 (Monroe et al., 2014) and leads to pyroptotic death of incompletely infected
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cells by initiating a cellular defence program involving the activation of caspase 1 (Doitsh et al.,
2010; Doitsh et al., 2014; Galloway et al., 2015). HIV proteins Tat and Env have also been shown
to lead to cell death of infected cells through CD95-mediated apoptosis following T-cell activation
(Banda et al., 1992; Westendorp et al., 1995a; Westendorp et al., 1995b1995). Using SIV infec-
tion, it has been shown that damage to lymph nodes due to chronic immune activation leads to an
environment less conducive to T-cell survival (Zeng et al., 2012). Finally, double strand breaks in the
host DNA caused by integration of the reverse transcribed virus results in cell death by the DNA-PK-
mediated activation of the p53 response (Cooper et al., 2013).
The lymph node environment is conducive to HIV infection due to: (1) presence of infectable cells
(Deleage et al., 2016; Embretson et al., 1993; Tenner-Racz et al., 1998); (2) proximity of cells to
each other and lack of flow which should enable cell-to-cell HIV spread (Baxter et al., 2014;
Dale et al., 2011; Groot et al., 2008; Groppelli et al., 2015; Gummuluru et al., 2002;
Hu¨bner et al., 2009; Jolly et al., 2004; Jolly et al., 2011; Mu¨nch et al., 2007; Sherer et al., 2007;
Sourisseau et al., 2007; Sowinski et al., 2008); (3) decreased penetration of antiretroviral therapy
(ART) (Fletcher et al., 2014a). Multiple infections per cell have been reported in cell-to-cell spread
of HIV (Baxter et al., 2014; Boulle´ et al., 2016; Dang et al., 2004; Del Portillo et al., 2011;
Dixit and Perelson, 2004; Duncan et al., 2013; Law et al., 2016; Reh et al., 2015; Russell et al.,
2013; Sigal et al., 2011; Zhong et al., 2013). In this mode of HIV transmission, an interaction
between the infected donor cell and the uninfected target results in directed transmission of large
numbers of virions (Baxter et al., 2014; Groppelli et al., 2015; Hu¨bner et al., 2009;
Sowinski et al., 2008). This is in contrast to cell-free infection, where free-floating virus finds target
eLife digest The HIVvirus infects cells of the immune system. Once inside, it hijacks the cellular
molecular machineries to make more copies of itself, which are then transmitted to new host cells.
HIV eventually kills most cells it infects, either in the steps leading to the infection of the cell, or after
the cell is already producing virus. HIV can spread between cells in two ways, known as cell-free or
cell-to-cell. In the first, individual viruses are released from infected cells and move randomly
through the body in the hope of finding new cells to infect. In the second, infected cells interact
directly with uninfected cells. The second method is often much more successful at infecting new
cells since they are exposed to multiple virus particles.
HIV infections can be controlled by using combinations of antiretroviral drugs, such as efavirenz,
to prevent the virus from making more of itself. With a high enough dose, the drugs can in theory
completely stop HIV infections, unless the virus becomes resistant to treatment. However, some
patients continue to use these drugs even after the virus they are infected with develops resistance.
It is not clear what effect taking ineffective, or partially effective, drugs has on how HIV progresses.
Using efavirenz, Jackson, Hunter et al. partially limited the spread of HIV between human cells
grown in the laboratory. The experiments mirrored the situation where a partially resistant HIV strain
spreads through the body. The results show that the success of cell-free infection is reduced as drug
dose increases. Yet paradoxically, in cell-to-cell infection, the presence of drug caused more cells to
become infected. This can be explained by the fact that, in cell-to-cell spread, each cell is exposed
to multiple copies of the virus. The drug dose reduced the number of viral copies per cell without
stopping the virus from infecting completely. The reduced number of viral copies per cell made it
more likely that infected cells would survive the infection long enough to produce virus particles
themselves.
Viruses that can kill cells, such as HIV, must balance the need to make more of themselves against
the speed that they kill their host cell to maximize the number of infected cells. If transmission
between cells is too effective and too many virus particles are delivered to the new cell, the virus
may not manage to infect new hosts before killing the old ones. These findings highlight this
delicate balance. They also indicate a potential issue in using drugs to treat partially resistant virus
strains. Without care, these treatments could increase the number of infected cells in the body,
potentially worsening the effects of living with HIV.
DOI: https://doi.org/10.7554/eLife.30134.002
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cells through diffusion. Both modes occur simultaneously when infected donor cells are cocultured
with targets. However, the cell-to-cell route is thought to be the main cause of multiple infections
per cell (Hu¨bner et al., 2009). In the lymph nodes, several studies showed multiple infections
(Gratton et al., 2000; Jung et al., 2002; Law et al., 2016) while another study did not
(Josefsson et al., 2013). One explanation for the divergent results is that different cell subsets are
infected to different degrees. For example, T cells were shown not to be multiply infected in the
peripheral blood compartment (Josefsson et al., 2011). However, more recent work investigating
markers associated with HIV latency in the face of ART found that the average number of HIV DNA
copies per cell is greater than one in 3 out of 12 individuals. This occurred in the face of ART in the
CD3-positive, CD32a high CD4 T-cell subset (Descours et al., 2017). In the absence of suppressive
ART, it would be expected that the number of HIV DNA copies per cell would be higher.
Multiple viral integration attempts per cell may increase the probability of death. One conse-
quence of HIV-mediated death may be that attenuation of infection may increase viral replication by
increasing the number of live targets. Indeed, it has been suggested that more attenuated HIV
strains result in more successful infections in terms of the ability of the virus to replicate in the
infected individual (Arie¨n et al., 2005; Nowak and May, 2000; Payne et al., 2014; Quin˜ones-
Mateu and Arts, 2006; Wodarz and Levy, 2007).
Here, we experimentally examined the effect of attenuating cell-to-cell spread by using HIV inhib-
itors. We observed that partially inhibiting infection with drug or antibody resulted in an increase in
the number of live infected cells in both a cell line and in lymph node cells. This is, to our knowledge,
the first experimental demonstration at the cellular level that attenuation of HIV infection can result
in an increase in live infected cells under specific infection conditions.
Results
We introduce a model of infection where each donor to target transmission leads to an infection
probability r and death probability q per infection attempt. In our experimental system, one infection
attempt is measured as one HIV DNA copy, whether integrated or unintegrated. The probability of
successful infection of a target cell given n infection attempts is 1-(1 r)n (Sigal et al., 2011). We
define Ln as the probability of a cell to survive infection in the face of n infection attempts. Assuming
infection attempts act independently, Ln=(1-q)
n. The probability of a cell to be infected and not die
after it has been exposed to n infection attempts is therefore:
Pn ¼ 1  1  rð Þ
nð Þ 1  qð Þn (1)
This model makes several simplifying assumptions: (1) all infection attempts have equal probabili-
ties to infect targets. (2) The probability for a cell to die from each transmission is equal between
transmissions. (3) Infection attempts act independently, and productive infection and death are inde-
pendent events. In this model, r and q capture the probabilities for a cell to be infected or die post-
reverse transcription. For example, mutations which reduce viral fitness by decreasing the probability
of HIV to integrate would reduce r, while mutations which reduce the probability of successful
reverse transcription would reduce n.
If the number of infection attempts n is Poisson distributed with mean l, the probability for a cell
to be infected is 1-e-rl and the probability of a cell to live is Ln = e
-ql (see Supplementary file 1 for
parameters and definitions). As derived in Appendix 1, the probability that a cell is productively
infected will be:
Pl ¼ e
 lq
1  e lr 1 qð Þ
 
(2)
Since antiretroviral drugs lead to a reduction in the number of infection attempts by, for example,
decreasing the probability of reverse transcription in the case of reverse transcriptase inhibitors, we
introduced a drug strength value d, where d = 1 in the absence of drug and d > 1 in the presence of
drug. In the presence of drug, l is decreased to l/d. The drug therefore tunes l, and if the antiretro-
viral regimen is fully suppressive, l/d is expected to be below what is required for ongoing replica-
tion. The probability of a cell to be infected and live given drug strength d is therefore:
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Pl=d ¼ e
 lq=d
1  e lr 1 qð Þ=d
 
(3)
Analysis of the probability of a cell to survive and be infected as a function of r and q shows that
at each drug strength d/l, Pl increases as the probability of infection r increases (Figure 1). Hence,
the value of r strongly influences the amplitude of Pl. How Pl behaves when drug strength d/l
increases depends on the parameter values of r and q. A subset of parameter values results in a
peak in the number of infected cells at intermediate d/l, decreasing as drug strength increases fur-
ther (Figure 1). We refer to such a peak in infected numbers as an infection optimum. As q
increases, the cost of multiple infections per cell increases, and the infection optimum shifts to
higher d/l values. A fall from the infection optimum at decreasing d/l is driven by increasing cell
death as a result of increasing infection attempts per cell. This slope is therefore shallower, and
peaks broader, at low q values (Figure 1).
Our model assumes that cellular infection and death due to an HIV infection attempt are indepen-
dent processes. This is based on observations that support a role for cell death as a cellular defence
mechanism which may occur before productive infection, such as programmed cell death triggered
by HIV integration induced DNA damage (Cooper et al., 2013). An alternative model is that HIV-
mediated cell death depends on productive infection. This would be consistent with cell death due
to, for example, expression of viral proteins (Westendorp et al., 1995b1995). Since the concentra-
tion of viral proteins may also scale with the number of infections per cell, we derived the mathemat-
ical model for such a process in the supplementary mathematical analysis. The models are
equivalent, showing that independence of cell death and infection is not a necessary condition for
an infection optimum to occur in the presence of inhibitor.
Figure 1. Probability for a cell to be infected and live as a function of inhibitor. Probability for a cell to be infected and live was calculated for 20
infection attempts (l) and represented as a heat map. Drug strength (d/l) is on the y-axis, and the probability per infection attempt to infect (r) is on
the x-axis. Each plot is the calculation for one value of the probability per infection attempt to die (q) denoted in white in the top left corner.
DOI: https://doi.org/10.7554/eLife.30134.003
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Given that an infection optimum is dependent on parameter values, we next examined whether
these parameter values occur experimentally in HIV infection. We therefore first tested for an infec-
tion optimum in the RevCEM cell line engineered to express GFP upon HIV Rev protein expression
(Wu et al., 2007). We subcloned the cell line to maximize the frequency of GFP-positive cells upon
infection (Boulle´ et al., 2016). We needed to detect the number of infection attempts per cell l. To
estimate this, we used PCR to detect the number of reverse transcribed copies of viral DNA in the
cell by splitting each individual infected cell over multiple wells. We then detected the number of
wells with HIV DNA by PCR amplification of the reverse transcriptase gene. Hence, the number of
positive wells indicated the minimum number of viral DNA copies per cell, since more than one copy
can be contained within the same well (Josefsson et al., 2011; Josefsson et al., 2013). We first
measured the number of viral DNA copies in ACH-2 cells, reported to contain a single inactive HIV
integration per genome (Chun et al., 1997; O’Doherty et al., 2002). We sorted a total of 166 ACH-
2 cells at one cell per well into lysis buffer and subdivided single-cell lysates into four wells (Fig-
ure 2—figure supplement 1A). About one quarter of cells showed a PCR product of the expected
size. Cells with more than one HIV copy per cell were very rare and may reflect either errors in cell
sorting or dividing cells (Figure 2—figure supplement 1B). Similar frequencies were obtained when
the ACH-2 cell line was subcloned or split over 10 wells (Figure 2—figure supplement 1C). Given
that each ACH-2 cell contains one HIV DNA copy, the frequency of detection indicated our detec-
tion efficiency per HIV DNA copy.
To investigate the effect of multiple infection attempts per cell, we used coculture infection,
where infected (donor) cells are co-incubated with uninfected (target) cells and lead to cell-to-cell
spread. We used approximately 2% infected donor cells as our input, and detected the number of
HIV DNA copies per cell by flow cytometric sorting of individual GFP-positive cells followed by split-
ting each cell lysate over 10 wells. Wells were then amplified by PCR and visualized on an agarose
gel (Figure 2A). We assayed 60 cells and obtained a wide distribution of viral DNA copies per cell,
which ranged from 0 to 9 copies (Figure 2B). The range of HIV DNA copies per cell fit a Poisson dis-
tribution with two means better than either a single mean Gaussian or Poisson distribution. However,
the fit of the two mean Poisson distribution did not show two obvious peaks, and instead seemed to
fit the data better due to the addition of fit parameters (Figure 2—figure supplement 2). Hence we
cannot conclude that the distribution is bimodal. We also detected the HIV copy number in 30 GFP-
positive cells infected by cell-free HIV. HIV in cell-free form was obtained by filtering supernatant
from HIV producing cells to exclude cells or cell fragments, then infecting target cells with the fil-
tered virus. Infection with this virus is defined here as cell-free infection. In this case, we detected
either zero or one HIV copy per cell (Figure 2B inset). The frequency of single HIV DNA copies was
0.23, identical to the measured result in the ACH-2 cell line. We computationally corrected the
detected number of DNA copies in coculture infection for the sensitivity of our PCR reaction as
determined by the ACH-2 results (Materials and methods). On average we obtained 15 ± 3 copies
per cell after correction.
To tune l, we added the HIV reverse transcriptase inhibitor efavirenz (EFV) to infections. To calcu-
late d, we used cell-free infection (Figure 2C, see Figure 2—figure supplement 3 for logarithmic
y-axis plot), which as verified above, results in single HIV copies per cell. For cell-free infection, we
approximate d = 1/Tx, where Tx is defined as the number of infected cells with drug divided by the
number of infected cells without drug with single infection attempts (see Materials and methods and
[(Sigal et al., 2011]). This is equivalent to 1-e in a commonly used model describing the effect of
inhibitors on infection. In this model, e is drug effectiveness, with the 50% inhibitory drug concentra-
tion (IC50) and the Hill coefficient for drug action as parameter values (Canini and Perelson, 2014;
Shen et al., 2008). We fit the observed response of infection to EFV using this approach to estimate
d across a range of EFV concentrations. Fit of the model to the cell-free data using wild type, EFV-
sensitive HIV showed a monotonic decrease with IC50 = 2.9 nM and Hill coefficient of 2.1
(Figure 2C, black line).
We next dialed in EFV to tune l/d in coculture infection. To obtain the number of infected target
cells, and specifically exclude donor cells or donor-target cell fusions, target cells were marked by
the expression of mCherry. Donor cells were stained with the vital stain Cell Trace Far Red (CTFR).
The concentration of live infected cells was determined after 2 days in coculture with infected
donors. Live infected cells were identified based on the absence of cell death indicator dye DAPI
fluorescence, and presence of GFP. The input of infected donor cells was excluded from the count
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Figure 2. Partial inhibition increases the number of live infected cells. (A) To quantify HIV DNA copy number per cell, GFP-positive cells were sorted
into individual wells and lysed. Each lysate was subdivided into 10 wells and PCR performed to detect HIV DNA, with the sum of positive wells being
the raw HIV copy number for that cell. (B) Histogram of raw HIV DNA copies per cell in coculture infection (n = 60 cells, four independent experiments).
Inset shows raw HIV DNA copies per cell in cell-free infection (n = 30, two independent experiments) (C) Number of live infected cells normalized by
maximum number of live infected cells in cell-free infection with EFV. Black line is best-fit for EFV suppression of cell-free infection (IC50 = 2.9 nM,
h = 2.1). Means and standard errors for three independent experiments. (D) Number of live infected cells/ml 2 days post-infection resulting from
coculture infection of 106 cells/ml in the presence of EFV. Means and standard errors for three independent experiments. Black line is best-fit of
Equation (3) with r = 0.22 and q = 0.17. Dashed green line is the result of Equation (3) with experimentally measured r = 0.28, q = 0.15.
DOI: https://doi.org/10.7554/eLife.30134.004
The following figure supplements are available for figure 2:
Figure supplement 1. Detected integrations in ACH-2 cells.
DOI: https://doi.org/10.7554/eLife.30134.005
Figure supplement 2. Fitting of different distributions to the frequency of HIV DNA copies per cell.
DOI: https://doi.org/10.7554/eLife.30134.006
Figure supplement 3. The number of live infected cells in cell-free infection with wild-type HIV.
DOI: https://doi.org/10.7554/eLife.30134.007
Figure supplement 4. Gating strategy for coculture infection with wild type HIV.
DOI: https://doi.org/10.7554/eLife.30134.008
Figure supplement 5. Experimental measurement of r and q.
DOI: https://doi.org/10.7554/eLife.30134.009
Figure 2 continued on next page
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of infected cells based on the absence of mCherry fluorescence. Donor-target cell fusions were
excluded by excluding CTFR-positive cells (see Figure 2—figure supplement 4 for gating strategy).
While the percent of infected cells was reduced with drug, the concentration of live infected cells
increased (Figure 2—figure supplement 4). We observed a peak in the number of live infected tar-
get cells at 4 nM EFV (Figure 2D). We then fit the number of live infected cells using Equation (3),
where Pl was multiplied by the input number of target cells per ml (10
6 cells/ml) to obtain the pre-
dicted number of live infected cells per ml of culture. This was done to constrain r in the model,
which strongly determines the amplitude of Pl/d as described above. Equation (3) best fit the
behaviour of infection when r = 0.22 and q = 0.17, resulting in a peak at 4.8 nM EFV (Figure 2D,
black line). Hence an infection optimum is present in the cell line infection system.
In order to determine whether the fitted r and q values were within a reasonable range, we mea-
sured these values experimentally. To measure r, we infected with cell-free HIV to avoid the broad
distribution of HIV copy numbers observed in cell-to-cell spread, and determined the fraction of live
infected cells Pl (Figure 2—figure supplement 5A). We then determined the mean number of HIV
copies per cell l for the same set of experiments corrected by the efficiency of detection (Figure 2—
figure supplement 5B). The parameter r was calculated as -ln(1-Pl)/l (Supplementary file 2). To
measure q, we blocked cell division using serum starvation to measure differences in cell concentra-
tion due to cell death only, and not due to proliferation of uninfected cells (Figure 2—figure supple-
ment 5C). We then infected with cell-free HIV and measured Ll, defined as the fraction of live cells
remaining upon infection with l HIV DNA copies relative to infection blocked with EFV (see below).
To specifically detect the decrease in live cells as a result of events downstream of reverse transcrip-
tion, we compared infected cells to cells exposed to the same virus concentration but treated with
40 nM EFV, a drug concentration where infection by cell-free virus is negligible (Figure 2—figure
supplement 3). q was then calculated as -ln(Ll)/l, where Ll was the probability of a cell to live given
transmission with l copies (Supplementary file 2). Measured r and q values were 0.28 ± 0.08 and
0.15 ± 0.07 (mean ±standard deviation), respectively. The solution to Equation (3) using these values
showed similar behavior to the solution with the fitted values for wild-type HIV infection, indicating
that the fitted values gave a reasonable approximation of the behavior of the system (Figure 2D,
dashed green line).
In order to investigate the dynamics of cell depletion due to cell-to-cell HIV spread and its modu-
lation by the addition of an inhibitor, we performed time-lapse microscopy over a two day infection
window. While infection parameters were different due to the constraints of visualizing cells (Materi-
als and methods), the general trend from the data was deterioration in the number of live cells in
the time-lapse culture starting at 1 day post-infection when no drug was added. The deterioration in
live cell numbers was averted by the addition of EFV (Figure 2—figure supplement 6).
We next investigated whether an infection optimum occurs with EFV-resistant HIV. To derive the
resistant mutant, we cultured wild-type HIV in our reporter cell line in the presence of EFV. We
obtained the L100I partially resistant mutant. We then replaced the reverse transcriptase of the wild-
type molecular clone with the mutant reverse transcriptase gene (Materials and methods). We
derived dmut for the L100I mutant using cell-free mutant infection (Figure 3A, see Figure 3—figure
supplement 1 for logarithmic y-axis plot). The L100I mutant was found to have an IC50 = 29 nM EFV
and a Hill coefficient of 2.0 (Figure 3A, black line).
We next performed coculture infection (see Figure 3—figure supplement 2 for gating strategy).
Similarly to wild-type HIV coculture infection, there was a peak in the number of live infected target
cells for the L100I mutant infection. However, the peak in live infected cells was shifted to 40 nM
EFV (Figure 3B). Fits were obtained to Equation (3) using dmut values and l measured for wild-type
infection. The fits recapitulated the experimental results when r = 0.29 and q = 0.13, with a fitted
peak at 45 nM EFV (Figure 3B, black line). The solution to Equation (3) using the measured values
for r and q showed a similar pattern to that obtained with the fitted values (Figure 3B, dashed green
line). We note that both wild type and mutant coculture infection has data points above the fit line
at the highest drug concentrations. This may be a limitation of our model at drug values much higher
Figure 2 continued
Figure supplement 6. Time-lapse microscopy of HIV infection in the absence and presence of EFV.
DOI: https://doi.org/10.7554/eLife.30134.010
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than observed at the infection optimum. In this range of drug values, our model predicts a more pro-
nounced decline in the number of infected cells than is observed experimentally.
In order to examine whether a peak in live infected targets can be obtained with an unrelated
inhibitor, we used the HIV neutralizing antibody b12. This antibody is effective against cell-to-cell
spread of HIV (Baxter et al., 2014; Reh et al., 2015). We obtained a peak in live infected cells at 5
ug/ml b12 (Figure 4). The b12 concentration that resulted in a peak number of live infected cells
was the same for wild-type virus and the L100I mutant, showing that L100I mutant fitness gain was
EFV specific. In contrast, cell-free infection in the face of b12 showed a sharp and monotonic drop in
live infected cells for both wild type and mutant virus (Figure 4—figure supplement 1).
While the RevCEM cell line is a useful tool to illustrate the principles governing the formation of
an infection optimum, the sensitivity of such an optimum to parameter values would make its pres-
ence in primary HIV target cells speculative. We therefore investigated whether a fitness optimum
occurs in primary human lymph node cells, the anatomical site which would be most likely to have a
high force of infection. We derived human lymph nodes from HIV-negative individuals from indicated
lung resections (Supplementary file 3), cellularized the lymph node tissue using mechanical separa-
tion, and infected the resulting lymph node cells with HIV. A fraction of the cells was infected by
cell-free virus and used as infected donor cells. We added these to uninfected target cells from the
same lymph node to test coculture infection, and detected the number of live infected cells 4 days
post-infection with the L100I EFV-resistant mutant in the face of EFV. We detected the number of
Figure 3. Partial inhibition of the EFV-resistant L100I mutant shifts the peak of live infected cells to higher EFV concentrations. (A) The number of live
infected cells normalized by the maximum number of live infected cells in cell-free infection as a function of EFV for the L100I mutant. Black line is best-
fit for EFV suppression of cell-free infection (IC50 = 29 nM, h = 2.0). Shown are means and standard errors for three independent experiments. (B)
Number of live infected cells/ml 2 days post-infection resulting from coculture infection of 106 cells/ml in the presence of EFV. Means and standard
errors for three independent experiments. Black line is best-fit of Equation (3) with r = 0.29 and q = 0.13. Dashed green line is the result of
Equation (3) with the experimentally measured r = 0.28 and q = 0.15 for wild-type HIV infection.
DOI: https://doi.org/10.7554/eLife.30134.011
The following figure supplements are available for figure 3:
Figure supplement 1. The number of live infected cells in cell-free infection with the L100I mutant.
DOI: https://doi.org/10.7554/eLife.30134.012
Figure supplement 2. Gating strategy for coculture infection with mutant HIV.
DOI: https://doi.org/10.7554/eLife.30134.013
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live infected cells by the exclusion of dead cells with the fixable death detection dye eFluor660 fol-
lowed by single cell staining for HIV Gag using anti-p24 antibody (Figure 5A).
In each of the lymph nodes tested, we observed a peak in live infected cells at intermediate EFV
concentrations. Lymph node cells from participant 205 showed a peak of live infected cells at 100
nM EFV (Figure 5A, first row). The infection optimum in the lymph node cells of study participant
257 was visible as a plateau between 50 and 200 nM EFV. In the presence of EFV, there was a
decrease in the fraction of dead cells that was offset by a similar increase in the fraction of live
infected cells for lymph nodes from all participants. There were more overall detectable cells with
EFV, resulting in differences in the absolute concentrations of live infected cells being larger than
the differences in the fractions of live infected cells between EFV and non-drug-treated cells (right
two columns in Figure 5A, with absolute number of live infected cells shown in parentheses in the
flow cytometry plots). This is most likely due to cells which died early becoming fragments and so
being excluded from the total population in the absence of EFV. Peaks in the number of live infected
cells in the face of drug may be specific to lymph node derived cells. Cell-to-cell infection of periph-
eral blood mononuclear cells (PBMC) with wild-type HIV showed a slight peak at a very low EFV con-
centration in cells from one blood donor, which was not repeated in cells from two other donors
(Figure 5—figure supplement 1).
Figure 4. Partial inhibition of coculture infection with neutralizing antibody results in higher numbers of live
infected cells. Shown are the numbers of live infected cells normalized by the maximum number of live infected
cells in coculture infection as a function of b12 antibody concentration. Infection was by either EFV-sensitive HIV
(blue) or the L100I EFV-resistant mutant (green). Dashed lines are a guide to the eye. Shown are means and
standard errors for three independent experiments.
DOI: https://doi.org/10.7554/eLife.30134.014
The following figure supplement is available for figure 4:
Figure supplement 1. The number of live infected cells with cell-free infection in the face of neutralizing antibody
b12.
DOI: https://doi.org/10.7554/eLife.30134.015
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Figure 5. Infection optimum with EFV in lymph node cells. (A) Number of live infected cells as a function of EFV.
Each row shows in vitro infected lymph node cells from one participant. Left column is the number of live infected
cells normalized by maximum number of live infected cells in coculture infection. Middle and right columns are
flow cytometry dot plots of infection without drug and at the infection optimum, with HIV p24 on x-axis and death
detection by eFluor660 on y-axis. Infected live cells are bottom right. Number in brackets represents live infected
cell density per ml. PID, participant identification number. For PID205 and 257, cells were sufficient for one
experiment. For PID251, means and standard errors for three independent experiments are shown. Dashed lines
are a guide to the eye. (B) HIV DNA copy number per cell was quantified by sorting fixed p24-positive cells from
PID251 into individual wells. Cells were lysed and de-crosslinking performed. Each lysate was divided into four
wells and PCR performed to detect HIV DNA. First row is representative of cells with no drug, second row is
representative of 40 nM EFV. (C) Mean and standard error of the number of HIV DNA copies without drug and
with 40 nM EFV after assay sensitivity correction. N = 56 cells from three independent experiments for each
condition. ****p=410 9, two tailed t-test.
DOI: https://doi.org/10.7554/eLife.30134.016
The following figure supplements are available for figure 5:
Figure 5 continued on next page
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We used a lymph node from study participant 251, where we obtained more cells, to examine
the number of HIV DNA copies per cell. Cells from this lymph node showed an infection optimum at
50 nM EFV (Figure 5A, third row). To detect the effect of EFV on integrations per cell, we sorted sin-
gle cells based on p24-positive signal, de-crosslinked to remove the fixative (Materials and meth-
ods), then divided each cell lysate into four wells. Using fewer wells saved reagents without
changing sensitivity, as demonstrated in the ACH-2 cell line (Figure 2—figure supplement 1C). We
detected HIV DNA copies by PCR 2 days post-infection. We observed multiple DNA copies in EFV-
untreated lymph node cells. The number of copies decreased with EFV (Figure 5B). We corrected
for sensitivity of detection as quantified in ACH-2 cells (Materials and methods). The corrected num-
bers were 21 HIV DNA copies with no drug, and five copies in the presence of EFV at the infection
optimum (Figure 5C, see Figure 5—figure supplement 2 for histograms of raw HIV DNA copy num-
bers per cell). Hence, the decrease in the number of copies still results in sufficient copies to infect
the cell.
Since L100I does not often occur in the absence of other drug resistance mutations according to
the Stanford HIV Drug Resistance Database (Rhee et al., 2003), we repeated the experiment with
the K103N mutant, a frequently observed mutation in virologic failure with a higher level of resis-
tance to EFV relative to the L100I mutant. We used cell-free infection to obtain drug inhibition per
virion at each level of EFV, which we denote d103 (Figure 6A, see Figure 6—figure supplement 1
for logarithmic y-axis plot). The fits showed a monotonic decrease with IC50 = 26.0 nM and Hill coef-
ficient of 1.5 (Figure 6A, black line). We then proceeded to use the K103N mutant in coculture infec-
tion, using cells from two different lymph nodes in different experiments (see Figure 6—figure
supplement 2 for results of individual experiments). We observed an infection optimum with EFV in
lymph node cells. The peak in the number of live infected cells in the presence of drug was between
80 and 160 nM EFV (Figure 6B). We fit the experimental data with Equation (3) using d103 values
and the number of DNA copies in the absence of drug measured for L100I infection. We did not cal-
culate the predicted number of infected cells for Pl/d values since the lymph node is a complex envi-
ronment containing different cell subsets (Sallusto et al., 1999) and the number of infectable target
cells at the start of infection is difficult to determine. Hence, we normalized both the experimental
number of live infected cells and the Pl/d values from Equation (3) to the maximum value in each
case. The fits recapitulated the experimental results when r = 0.91 and q = 0.15, with a fitted peak
at 90 nM EFV (Figure 6B, black line). The q value matched the measured result in the cell line, while
the r value was much higher. However, the fitted r value in this case is not expected to be accurate
since we were unable to constrain it with the number of infected cells relative to the starting number
of target cells.
To examine if the observed peak in live cells may be due to EFV alone, we measured cell viability
in lymph node cells from one of the study participants used in the above experiment as a function of
EFV without infection. No clear dependence on EFV in the absence of infection was detected (Fig-
ure 6—figure supplement 3).
Discussion
The optimal virulence concept in ecology proposes that virulence needs to be balanced against host
survival for optimal pathogen spread (Bonhoeffer et al., 1996; Bonhoeffer and Nowak, 1994;
Gandon et al., 2001; Jensen et al., 2006). At the cellular level, this implies that the number of suc-
cessfully infected cells may increase when infection virulence is reduced. The current study is, to our
knowledge, the first to address this question experimentally at the level of individual cells infected
with HIV.
Figure 5 continued
Figure supplement 1. Cell-to-cell infection of peripheral blood mononuclear cells in the presence of EFV does
not lead to a discernable peak in live infected cells.
DOI: https://doi.org/10.7554/eLife.30134.017
Figure supplement 2. Raw HIV DNA copy numbers per lymph node cell.
DOI: https://doi.org/10.7554/eLife.30134.018
Jackson et al. eLife 2018;7:e30134. DOI: https://doi.org/10.7554/eLife.30134 11 of 24
Research article Computational and Systems Biology Microbiology and Infectious Disease
Page 44 of Thesis
Using a model where cells are infected and die in a probabilistic way, we found that there were
two possible outcomes of partially inhibiting infection. In the case where cells were infected by single
infection attempts, inhibition always led to a decline in the number of live infected cells, since inhibi-
tion reduced the number of infections per cell from one to zero. In contrast, in the case of multiple
infection attempts per cell, the possibility existed that inhibition reduced the number of integrating
HIV DNA copies, without extinguishing infection of the cell completely. If each HIV DNA copy
increases the probability of cell death, reducing the number of HIV DNA copies without eliminating
infection should lead to an increased probability of infected cell survival. This would consequently
lead to an increase in the number of live infected cells.
We investigated the outcome of partial inhibition of infection in both a cell line and primary lymph
node cells. In both systems, we observed that there was a peak in live infected cell number at inter-
mediate inhibitor concentrations. This correlated to a decreased number of viral DNA copies per
cell. Further increasing inhibitor concentration led to a decline in live infected cell numbers, and
infecting with EFV resistant mutants shifted the peak in live infected number to higher EFV concen-
trations. Our model as described by Equation (3) reproduced the essential behaviour of the experi-
mental results. Construction of the model assumed independence of productive infection and cell
Figure 6. Infection with the K103N mutant shows an infection optimum at clinically observed lymph node EFV concentrations. (A) The number of live
infected cells normalized by the maximum number of live infected cells in cell-free infection as a function of EFV for the K103N mutant. Black line is
best-fit for EFV suppression of cell-free infection (IC50 = 26 nM, h = 1.5). Shown are means and standard errors for two independent experiments using
cells from PID251. (B) The number of live infected cells normalized by the maximum number of live infected cells in coculture infection as a function of
EFV for the K103N mutant. Black line represents best-fit model for the effect of EFV on coculture infection according to Equation (3), with d values
calculated based on the cell-free infection data for the K103N mutant, and the mean number of HIV DNA copies in the absence of drug determined for
L100I. The fits recapitulated the experimental results when r = 0.91 and q = 0.15. Shown are means and standard errors for three independent
experiments. There were sufficient lymph node cells from PID251 for two of the three experiments, and the third experiment was performed with lymph
node cells from PID274.
DOI: https://doi.org/10.7554/eLife.30134.019
The following figure supplements are available for figure 6:
Figure supplement 1. The number of live infected cells in cell-free infection with the K103N mutant.
DOI: https://doi.org/10.7554/eLife.30134.020
Figure supplement 2. Response of K103N coculture infection to EFV in individual experiments.
DOI: https://doi.org/10.7554/eLife.30134.021
Figure supplement 3. Effect of EFV on viability of uninfected lymph node cells from PID274.
DOI: https://doi.org/10.7554/eLife.30134.022
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death. However, as shown in the Appendix 1, an equivalent model can be constructed assuming a
dependence of cell death on infection. Neither model accurately captures infection dynamics at
high-drug concentrations, away from the infection optimum. In this range, where the number of
infection attempts per cell is much lower than 1, infection declined more slowly with drug than pre-
dicted. The model can be further refined using a distribution for the number of DNA copies per cell.
Moreover, the probability of death per HIV DNA copy we denote q may be dependent on how
many infection attempts preceded the current infection attempt, and the model can be improved by
measuring this dependence.
Physiologically, an infection optimum in the face of an antiretroviral drug may be important in HIV
infection of lymph node cells and may be less pronounced in cells from peripheral blood. We used
EFV in our study since it is a common component of first line antiretroviral therapy, with frequent
drug resistance mutations. However, the infection optimum we describe should occur with other
classes of antiretroviral drugs, since all drugs should decrease the multiplicity of infection between
cells. In terms of modeling, a future therapy component such as the integrase inhibitor dolutegravir
would exert its effect on r and not l in our model. However, the effect is symmetrical since e-(l/d)
r = e-l(r/d). The more complex outcome of partial inhibition of infection should also be considered in
other infections where multiple pathogens infect one cell and host cell death is a possible outcome
(Mahamed et al., 2017).
These observations reinforce previous results showing that successful completion of reverse tran-
scription leads to cellular cytotoxicity. In addition to HIV cytotoxicity caused by viral integrations
through the mechanism of double strand breaks (Cooper et al., 2013), other mechanisms of HIV-
induced death are also present, including IFI16-dependent innate immune system sensing of abor-
tive reverse transcripts following non-productive infection of resting T cells (Doitsh et al., 2014;
Monroe et al., 2014). The experiments presented here reflect the effect of partial inhibition on pro-
ductive infection of HIV target cells, which mostly consist of activated T-cell subsets, not resting T
cells. More complex models would be needed to decipher the effect of partial inhibition of HIV
infection on resting T-cell numbers and the outcome of this in terms of available T-cell targets in
future infection cycles.
This study may have implications for the establishment of viral reservoirs in the context of poorly
controlled infections, infections with some degree of drug resistance, or infections where some repli-
cation may take place in the face of ART, since infected cell survival is a pre-requisite for long-term
persistence. The clinical implications of an infection optimum in the presence of EFV with EFV-sensi-
tive HIV strains are likely to be negligible, since the drug concentrations at which the infection opti-
mum occurs are extremely low. However, for EFV-resistant HIV, the infection optimum shifts to the
range of EFV concentrations observed in lymph nodes (~100 nM) (Fletcher et al., 2014b), and can
be expected to shift to even higher EFV concentrations with more resistant mutants. As EFV has a
longer half-life than the other antiretroviral drugs co-formulated with it, it may be the only agent
present in partially adherent individuals for substantial periods of time (Taylor et al., 2007). There-
fore, partial inhibition of HIV infection with EFV may provide a surprising advantage to EFV resistant
mutants, and may allow individuals failing therapy to better transmit drug resistant strains.
Materials and methods
Ethical statement
Lymph nodes were obtained from the field of surgery of participants undergoing surgery for diag-
nostic purposes and/or complications of inflammatory lung disease. Informed consent was obtained
from each participant, and the study protocol approved by the University of KwaZulu-Natal Institu-
tional Review Board (approval BE024/09). Blood for PBMC was obtained from healthy blood donors
under the same study protocol.
Inhibitors, viruses and cell lines
The following reagents were obtained through the AIDS Research and Reference Reagent Program,
National Institute of Allergy and Infectious Diseases, National Institutes of Health: the antiretroviral
EFV; RevCEM cells from Y. Wu and J. Marsh; HIV molecular clone pNL4-3 from M. Martin; ACH-2
cells from T. Folks. Cell-free viruses were produced by transfection of HEK293 cells with pNL4-3
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using TransIT-LT1 (Mirus, Madison, WI ) or Fugene HD (Roche, Risch-Rotkreuz, Switzerland) transfec-
tion reagents. Virus containing supernatant was harvested after 2 days of incubation and filtered
through a 0.45 mm filter (Corning, New York, NY). b12 antibody was produced from transfecting
HEK293 cells with a b12 expression plasmid (expressed under a CMV promoter on a pHAGE6 lentivi-
ral plasmid backbone, gift from A. Balazs), followed by harvesting of cell supernatant and purifica-
tion at the California Institute of Technology protein expression core. The number of virus genomes
in viral stocks was determined using the RealTime HIV-1 viral load test (Abbott Diagnostics, Santa
Clara, CA). For r and q measurement, 0.45 mm filtered cell-free supernatants from infected RevCEM
cells were used, to include any secreted factors which may modulate cell-death. The L100I and
K103N mutants were evolved by serial passages of wild-type NL4-3 in RevCEM cells in the presence
of 20 nM EFV. After 16 days of selection, the reverse transcriptase gene was cloned from the proviral
DNA and the mutant reverse transcriptase gene was inserted into the NL4-3 molecular clone.
RevCEM clones E7 and G2 used in this study were generated as previously described (Boulle´ et al.,
2016). Briefly, the E7 clone was generated by subcloning RevCEM cells at single-cell density. Surviv-
ing clones were subdivided into replicate plates. One of the plates was screened for the fraction of
GFP expressing cells upon HIV infection using microscopy, and the clone with the highest fraction of
GFP-positive cells was selected. To generate the G2 clone, E7 cells were stably infected with the
mCherry gene under the EF-1a promoter on a pHAGE2-based lentiviral vector (gift from A. Balazs),
subcloned, and screened for >99% mCherry-positive cells. All cell lines not authenticated, and myco-
plasma negative. Cell culture and experiments were performed in complete RPMI 1640 medium sup-
plemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids
(Lonza, Basel, Switzerland), and 10% heat-inactivated FBS (GE Healthcare Bio-Sciences, Pittsburgh,
PA).
Primary cells
Lymph node cells were obtained by mechanical separation of lymph nodes and frozen at 5  106
cells/ml in a solution of 90% FBS and 10% DMSO with 2.5 mg/ml Amphotericin B (Lonza). Cells were
stored in liquid nitrogen until use, then thawed and resuspended at 106 cells/ml in complete RPMI
1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids
(Lonza), 10% heat-inactivated FBS (Hyclone), and IL-2 at 5 ng/ml (PeproTech). Phytohemagglutinin at
10 mg/ml (Sigma-Aldrich, St Louis, MO) was added to activate cells. PBMCs were isolated by density
gradient centrifugation using Histopaque 1077 (Sigma-Aldrich) and cultured at 106 cells/ml in com-
plete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential
amino acids (Lonza), 10% heat-inactivated FBS (GE Healthcare Bio-Sciences, Pittsburgh, PA), and IL-
2 at 5 ng/ml (PeproTech, Rocky Hill, NJ). Phytohemagglutinin at 10 mg/ml (Sigma-Aldrich) was added
to activate cells. For both primary cell types, donor cells for coculture infection were cultured for
one day then infected by cell-free virus, while target cells were cultured for three days and infected
with either cell-free HIV or infected donor cells.
Subcloning of ACH-2 cells
Cells from the parental ACH-2 cell line were diluted to 10 cells/ml in conditioned medium, with con-
ditioned medium generated by culturing ACH-2 cells to 106 cells/ml, then filtering through a 0.22
mm filter (Corning). 25 ml of the diluted cell suspension was then distributed to each well of a Greiner
mClear 384-well plate (mean of 0.5 cells per well). Clones were cultured for 3 weeks, where each
week an additional 25 ml of conditioned medium was added to each well. Clones were detected in
5% of wells and two clones, designated D6 and C3, were randomly chosen and further expanded.
Infection
For a cell-free infection of RevCEM clones, PBMC and lymph node cells, 106 cells/ml were infected
with 2  108 NL4-3 viral copies/ml (~20ng p24 equivalent) for 2 days. For coculture infection,
infected cells from the cell-free infection were used as the donors and cocultured with 106 cells/ml
target cells. For RevCEM clones, 2% infected donor cells were added to uninfected targets and
cocultured for 2 days in tissue culture experiments, and 20% infected donor cells were added to
uninfected targets and cocultured for 2 days for time-lapse experiments. For lymph node cells and
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PBMCs, a ratio of 1:4 donor to targets cells was used. Infection was over 2 days in PBMC infection
and for 4 days for infection of lymph node cells.
Staining and flow cytometry
To determine the number of live infected cells in reporter cell line experiments, E7 RevCEM reporter
cells were infected as above used as donor cells. Prior to co-incubation with target cells, donor cells
were stained with CellTrace Far Red (CTFR, Thermo Fisher Scientific, Waltham, MA) at 1 mM and
washed according to manufacturer’s instructions. The G2 mCherry-positive reporter cells were used
as infection targets, and cocultured with 2% infected donor cells for 2 days. The coculture infection
was pulsed with 100 ng/ml DAPI (Sigma-Aldrich) immediately before flow cytometry and the number
of live infected targets cells was determined by the number of DAPI negative, CTFR negative and
mCherry and GFP double positive cells on a FACSAria Fusion machine (BD Biosciences, Sparks, MD)
using the 355, 488 and 633 nm laser lines. For cell-free infections where fewer fluorescence channels
were used, a pulse of 300 nM of the far-red live cell impermeable dye DRAQ7 (Biolegend, San
Diego, CA) immediately before flow cytometry was substituted for DAPI, and live infected cells
detected as the number of DRAQ7-negative, GFP-positive cells on a FACSCaliber machine using
488 and 633 nm laser lines. Lymph node cells were resuspended in 1 ml of phosphate buffered saline
(PBS) and stained at a 1:1000 dilution of the eFlour660 dye (Thermo Fisher Scientific) according to
the manufacturer’s instructions. Cells were then fixed and permeabilized using the BD Cytofix/Cyto-
perm Fixation/Permeabilization kit (BD Biosciences) according to the manufacturer’s instructions.
Cells were then stained with anti-p24 FITC conjugated antibody (KC57, Beckman Coulter, Brea, CA).
Live infected lymph node cells were detected as the number of eFluor660-negative, p24-positive
cells. Cells were acquired with a FACSAriaIII or FACSCaliber machine (BD Biosciences) using 488
and 633 nm laser lines. Results were analysed with FlowJo 10.0.8 software. For single-cell sorting to
detect the number of HIV DNA copies per cell, cells were single-cell sorted using 85 micron nozzle
in a FACSAriaIII machine. GFP-positive, DRAQ7-negative RevCEM clones were sorted 1 day post-
infection into 96 well plates (Biorad, Hercules, CA) containing 30 ml lysis buffer (2.5 ml 0.1M Dithio-
threitol, 5 ml 5% NP40 and 22.5 ml molecular biology grade water [Kurimoto et al., 2007]). For
experiments to determine the number of HIV DNA copies to measure r and q, the DRAQ7-negative
subset was sorted. Fixed, p24-positive, eFluor660-negative lymph node cells were single-cell sorted
two days post-infection into 96-well plates containing 5 ml of PKD buffer (Qiagen, Hilden, Germany)
with 1:16 proteinase K solution (Qiagen) (Thomsen et al., 2016). Sorted plates were snap frozen
and kept at  80˚C until ready for PCR. For analysis by flow cytometry, a minimum of 50,000 cells
were collected per data point.
Time-lapse microscopy and image analysis
For imaging infection by time-lapse microscopy, cell density was reduced to 5  104 cells/ml and
cells were attached to ploy-l-lysine (Sigma-Aldrich) coated optical six-well plates (MatTek, Ashland,
MA). Infections with and without EFV were imaged in tandem using a Metamorph-controlled Nikon
TiE motorized microscope with a Yokogawa spinning disk with a 20x, 0.75 NA phase objective in a
biosafety level three facility. Excitation sources were 488 (GFP) and 561 (mCherry) laser lines and
emission was detected through a Semrock Brightline quad band 440–40/521–21/607-34/700-45 nm
filter. Images were captured using an 888 EMCCD camera (Andor, Belfast, UK). Temperature (37˚C),
humidity and CO2 (5%) were controlled using an environmental chamber (OKO Labs, Naples, Italy).
Fields of view were captured every 20 min. To facilitate automated image analysis of time-lapse
experiment data, mCherry expressing G2 clone cells were used as targets and E7 clone cells used as
infected donors. The number of live cells was measured as the number of cells expressing mCherry
since intracellular mCherry protein is soluble and hence lost upon cell death when cellular membrane
integrity is compromised. The number of live infected cells was measured as the number of cells
expressing both mCherry and GFP. Three independent experiments were performed. Movies were
analyzed using custom code developed with the Matlab R2014a Image Analysis Toolbox. Images in
the mCherry channel were thresholded and the imfindcircle function used to detect round objects
within the cell radius range. Cell centers were found. GFP signal underwent the same binary thresh-
olding. The number of mCherry-positive 16 pixel2 squares around the cell centers was used as the as
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the number of total target cells at each time-point, and the number of squares double positive for
fluorescence in the GFP channel was used as the number of infected target cells.
Determination of HIV DNA copy number in individual cells
96-well plates of cells previously sorted at 1 cell per well were thawed at room temperature and
spun down. Fixed cells were de-crosslinked by incubating in a thermocycler at 56˚C for 1 hr. The
lysate from each well was split equally over 10 wells (2.5 ml each well after correction for evaporation)
for E7 RevCEM or four wells (6.8 ml each well after correction for evaporation) for lymph nodes, con-
taining 50 ml of Phusion hot start II DNA polymerase (New England Biolabs, Ipswich, MA) PCR reac-
tion mix (10 ml 5X Phusion HF buffer, 1 ml dNTPs, 2.5 ml of the forward primer, 2.5 ml of the reverse
primer, 0.5 ml Phusion hot start II DNA polymerase, 2.5 ml of DMSO and molecular biology grade
water to 50 ml reaction volume). Two rounds of PCR were performed. The first round reaction ampli-
fied a 700 bp region of the reverse transcriptase gene using the forward primer 5’ CCTACACCTG
TCAACATAATTGGAAG 3’ and reverse primer 5’ GAATGGAGGTTCTTTCTGATG 3’. Cycling pro-
gram was 98˚C for 30 s, then 34 cycles of 98˚C for 10 s, 63˚C for 30 s and 72˚C for 15 s with a final
extension of 72˚C for 5 min. 1 ml of the first round product was then transferred into a PCR mix as
above, with nested second round primers (forward 5’ TAAAAGCATTAGTAGAAATTTGTACAGA 3’,
reverse 5’ GGTAAATCCCCACCTCAACAGATG 3’). The second round PCR amplified a 550 bp prod-
uct which was then visualized on a 1% agarose gel. PCR reactions were found to work best if sorted
plates were thawed no more than once, and plates which underwent repeated freeze-thaw cycles
showed poor amplification.
Correction of raw number of detected DNA copies for detection
sensitivity
A stochastic simulation in Matlab was used to generate a distribution for the number of positive
wells per cell for each mean number of DNA copies per cell l. The probability for a DNA copy to be
present within a given well and be detected was set as s/w, where s was the detection sensitivity
calculated as the number of ACH-2 with detectable integrations divided by the total number of
ACH-2 cells assayed (38/166, s = 0.23), and w was the number of wells. A random number m repre-
senting DNA copies per cell from a Poisson distribution with a mean l was drawn, and a vector R of
m random numbers from a uniform distribution was generated. If there existed an element Ri of the
vector with a value between 0 and s/w, the first well was occupied. If an element existed with a
value between s/w+g and 2(s/w), where g <<1, the second well was occupied, and if between (s/w
+g)(n-1) and n(s/w), the nth well was occupied. The sum of wells occupied at least once was deter-
mined, and the process repeated j times for each l, where j was the number of cells in the experi-
mental data. A least squares fit was performed to select l which best fit the experimental results
across well frequencies, and mean and standard deviation for l was derived by repeating the simula-
tion 10 times.
Fit of the EFV response for single infections using IC50 and Hill
coefficient
To obtain d, we normalized Equation (2) by the fraction of infected cells in the absence of drug
(Sigal et al., 2011) to obtain Tx = (infected targets with EFV)/ (infected targets no EFV)= ((1- (1 r)l/d)
(1-q)l/d)/ ((1- (1 r)l) (1-q)l). We approximate the result at small r, q to Tx = (1- e-rl/d) e-ql/d/ (1- e-rl) e-
ql=eqql(1-1/d) ((1- e-rl/d) / (1- e-rl)). Expanding the exponentials we obtain Tx = (1 + ql(1–1/d)) ((-rl/
d)/-rl) = (1 + ql(1–1/d))(1/d). We note that at l <1, ql(1–1/d)<<1, and hence Tx ffi 1/d. Tx was mea-
sured from the experiments to obtain d values at the EFV concentrations used for cell-free infection,
where l < 1. To obtain a fit of d as a function of the concentration of drug that gives half-maximal
inhibition (IC50) and Hill coefficient (h) for EFV, we used the relation for the fraction cells remaining
infected in the face of drug (Canini and Perelson, 2014), whose definition is equivalent to Tx at
l < 1:
1
d
¼ 1  ¼ 1 
EFV½ h
EFV½ hþICh
50
: (4)
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Measurement of r
Cell-free supernatant used in infection was derived as follows: 106 cells/ml were infected with 2 
108 NL4-3 viral copies/ml (~20ng p24 equivalent) for 2 days. Thereafter 0.2% of the infected cells
from the cell-free infection were added to 106 cells/ml target cells. The infected supernatant from
the coculture 2 days post-infection was filtered using a 0.45 mm filter (Corning) and added to cells at
a 1:8 dilution, where the dilution was calibrated to result in non-saturating infection in terms of GFP
expression. A fraction of the cells were sorted into lysis buffer at one cell per well 1 day post infec-
tion, split over four wells, and PCR performed as described above to determine HIV copy number
per cell. The remaining cells from the same infection were used to determine frequency of DRAQ-7-
negative, GFP-positive cells 2 days post-infection using flow cytometry.
Measurement of q
Cell-free supernatant used in infection was derived as for r, except that 1 day before harvesting of
the viral supernatant from infected cells, infected cells were washed twice with PBS and serum-free
growth medium added. At the same time, the target cells for the infection were washed twice with
PBS and serum-free growth medium added. Cells were split into two wells, and EFV to a final con-
centration of 40 nM was added to one of the wells. Supernatant was harvested and filtered as
described for r, and added to cells at a 1:2 dilution. A fraction of the cells were sorted into lysis
buffer at one cell per well 1 day post-infection, split over four wells, and PCR performed as
described above to determine HIV copy number per cell. The remaining cells from the same infec-
tion were used to determine the frequency of live and dead cells two days post-infection. The con-
centration of live cells was measured using the TC20TM automated cell counter (Bio-Rad) with trypan
blue staining (Lonza).
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Appendix 1
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Supplementary Mathematical Analysis for Jackson et al.
I Derivation of infection model assuming independence of infection
and cell death
We consider a model of infection where is the probability of one HIV DNA copy to successfully
infect the cell and is the probability of the cell to die as a result of the infection attempt. The
probability of being infected when virions enter the cell is:
Pn ¼ ð1 ð1  rÞ
nÞð1  qÞn : (AE1)
If the number of infection attempts, n, is Poisson distributed with mean l, the fraction of
cells that are productively infected is:
Pl ¼ e
 l
P
n
ln
n!
Pn ¼ e
 l
P
n
ln
n!
ð1 ð1  rÞnÞð1  qÞn
¼ e l
P
n
ðlð1 qÞÞn
n!
  ðlð1 rÞð1 qÞÞ
n
n!
¼ e lqð1  e lrð1 qÞÞ:
(AE2)
We introduce a drug strength value d, where d ¼ 1 in the absence of drug and d>1 in the
presence of drug. In the presence of drug, l is decreased to l=d. The drug therefore tunes l.
The probability of a cell to be infected and live given drug strength d is therefore:
Pl=d ¼ e
 lq=dð1  e lrð1 qÞ=dÞ: (AE3)
Experimentally, we measure Pl, the number of infected cells, and Ll, the number of live
cells remaining two days post-infection for the cell line.
Assuming a Poisson distribution of the number of infection attempts, the probability of
being productively infected is
Pl ¼ 1  e
 lr ) r¼ 
logð1 PlÞ
l
: (AE4)
Similarly, the probability of a cell to live is
Ll ¼ e
 lq ) q¼ 
logðLlÞ
l
: (AE5)
II Derivation of infection model assuming dependence of infection
and cell death
Cellular infection and death may be the result of independent processes. For example, cell
death may be a programmed response to DNA damage induced by the infection attempt and
therefore may occur regardless of whether or not the cell is successfully infected. Infection and
death may also be dependent. One example of dependence is the cytotoxicity mediated by
expressed viral proteins after integration into the host genome.
In this case, the probability of productive infection and survival of the cell given n attempts
is
Pn ¼
Xn
m¼1
n
m
 
ðr0ð1  q0ÞÞmð1  r0Þn m (AE6)
Here, r0 and q0 are the probabilities for infection and death respectively. Their relationship
to the experimentally measured r and q are discussed in the next section. r0ð1  q0Þ½ m is the
probability that m infection attempts are successful and none of the attempts triggers cell
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death, while ð1  r0Þn m accounts for n  m unsuccessful infections. To obtain the total
probability of productive infection without cell death given n attempts, we sum over all cases
with m0  1 sucessful infections.
Realizing that:
Pn
m¼1
n
m
  
ðr0ð1  q0ÞÞmð1  r0Þn m ¼
Pn
m¼0
n
m
  
ðrð1  qÞÞmð1  r0Þn m ð1  r0Þn
¼ ðr0ð1  q0Þþ ð1  r0ÞÞn ð1  r0Þn ;
(AE7)
we can simplify the above to:
Pn ¼ ðr
0ð1  q0Þþ ð1  r0ÞÞn ð1  r0Þn ¼ ð1  r0q0Þn ð1  r0Þn: (AE8)
Averaging this over a Poisson distribution with meanl, we find:
e l
X
n
ln
n!
Pn ¼ e
 l
X
n
ln
n!
ðð1  r0q0Þn ð1  r0ÞnÞ ¼ e lr
0q0   e lr
0
: (AE9)
III Equivalence of the two models
The two models predict same dependence on l (the difference of two exponentials) but the
parameters r; q and r0; q0 play slightly different roles. The models are the same if:
r0q0 ¼ q and r0 ¼ rð1  qÞþ q: (AE10)
Hence the two models are a re-parametrization of the same process. The experimental
measurement of r and q, as described in the main manuscript, consists of estimating r as the
fraction of infected cells when the fraction of dead cells is low due to a low number of
measured DNA copies per cell. The death rate q is derived by measuring the number of live
cells remaining when the number of HIV DNA copies per cell is known. If the probability of
death is dependent on infection, then death is only of infected cells and is a product of the
probability to be infected and die (r0q0). Likewise, the underlying probability of infection r0 will
account for the fraction dead cells (q) and any cells which are infected but not dead (rð1  qÞ).
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12
Abstract HIV exists as multiple genotypes in a single infected individual, referred to as a13
quasispecies. How such sequence heterogeneity can be maintained in the same environment14
remains unclear. Here we reproduced a quasispecies in vitro by using the antiretroviral drug15
efavirenz (EFV) as the selective pressure. We observed that while the frequency of EFV resistant16
mutant virus increased with time, it never completely supplanted the wildtype genotype. Instead,17
the wildtype stabilized at 20 percent of the virus population. Single-cell sequencing of viral18
genotypes showed that the fraction of drug resistant virus in the population increased when the19
majority of cells were infected with wild type virus only, but plateaued when cells were co-infected20
with wildtype and mutant. This suggests that in co-infected cells, wildtype virus may package21
mutant reverse transcriptase (RT) and vice versa otherwise known as complementation. To test for22
complementation, we singly transfected CFP labelled wildtype and YFP labelled EFV resistant23
mutant molecular viral clones, or co-transfected both. When virus made by transfected cells was24
tested, YFP and CFP expressing virus was similarly resistant to EFV in the co-transfection, but25
followed the expected resistance pattern in single transfections. These results indicate that26
complementation is one mechanism which drives quasispecies formation.27
28
Introduction29
The HIV quasispecies consist of multiple viral genomes sampled from an environment such as the30
blood. One consequence of a quasispecies is diversity in the HIV Env gene. This allows HIV to escape31
neutralizing antibodies (Frost et al. (2005); Rong et al. (2009)). In the face of antiretroviral therapy, a32
quasispecies is formed which results in a mixture of HIV genomes that are resistant to different33
degrees to antiretroviral drugs (ARVs) (Brenner et al. (2002); Allers et al. (2007)). A quasispecies may34
also allow HIV to maintain sufficient heterogeneity to escape effective T cell suppression (Phillips35
et al. (1991); Goulder et al. (2001)).36
Due to the errors in reverse transcription, HIV replication generates a quasispecies where37
variants are at low frequencies around the main viral sequence (Brenner et al. (2002); Coffin (1992);38
Katz and Skalka (1990). However, how a stable quasispecies with variants at high frequencies is39
maintained is unclear. One possibility is that different anatomical environments apply different40
1 of 10
Page 58 of Thesis
selective pressures, therefore leading to a diverse viral pool (Paranjpe et al. (2002); Schnell et al.41
(2010)). One mechanism to create a quasispecies that does not rely on the assumption of different42
environments is complementation or phenotypic mixing (Domingo et al. (2012); Hill et al. (2012)).43
In this mechanism, co-infection and viral protein expression from two different viral genotypes in44
the same cell results in sharing of viral components. This mechanism is distinct from recombination,45
where two viral genomes co-packaged in the same cell recombine to form a new genome (Levy et al.46
(2004)). In complementation, a virus of genotype 1 may contain proteins from virus of genotype47
2 and vice versa. If one of the genotypes has a fitness cost relative to the other, the difference in48
fitness will be masked (Andino and Domingo (2015)). This process has been shown to operate in49
viruses (Froissart et al. (2004); Vignuzzi et al. (2006)) including HIV (Mo et al. (2004); Gelderblom50
et al. (2008)). There is no known mechanism which prevents one HIV strain packaging components51
such as RT from another HIV strain if both strains are in the same cell since RT molecules mix in the52
cell cytoplasm (Freed (2001)).53
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Figure 1. Frequency of EFV resistant mutant plateaus in the face of EFV selection. (A) The fraction of infectedcells as a function of time in the presence of 20 nM EFV. Mean and standard deviation of 3 independentexperiments. (B) Frequency of EFV resistant mutants as a function of time derived from population illuminasequencing of the cell population for cell populations from (A). Mean and standard deviation of 3 independentexperiments.
Here we used in vitro HIV evolution in the presence of RT inhibitor EFV to ask whether a quasis-54
pecies can be formed by complementation. We observed that drug resistant mutant reproducibly55
evolved during infection in the face of EFV. Initially, mutant infection rapidly expanded. However,56
once the fraction of mutant infected cells reached 0.8, the frequency of mutant stabilized. This57
correlated with co-infection of wild-type and mutant genomes, and such co-infection led to virions58
with wild type or mutant genotypes displaying a similar level of EFV resistance. This shows that59
complementation should have an important role in the formation of the quasispecies during HIV60
drug resistant evolution.61
Results62
To test whether a quasispecies can be reproduced in vitro, we infected the RevCEM E7 clone63
(Boullé et al. (2016); Jackson et al. (2018)) with HIV in the face of inhibition by EFV. This clone of the64
RevCEM cell line expresses GFP in the presence of the HIV Rev protein (Wu et al. (2007)), with the65
maximum frequency of GFP positive cells being over 80 percent (Jackson et al. (2018)). Infection66
was maintained at 2 percent of the total cell population by diluting infected cells every 2 days. The67
number of infected cells at the end of each two day cycle, before dilution, was 10 percent, resulting68
in a replication ratio (R) of approximately 5. It then increased moderately on day 10 and sharply on69
day 12, indicating that the evolution of drug resistance has taken place (Fig 1A). Illumina sequencing70
of the HIV DNA population at each day showed that starting day 10, the L100Imutation in the HIV71
RT gene, which confers resistance to EFV, was detected at a frequency of 10 percent of the total72
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viral genomes (Fig 1A). This reached about 60 percent on day 12 and 80 percent on day 14. The73
L100I frequency stabilized at 80 percent on day 16 and day 18. Other EFV resistant mutants, such74
as K103N, accounted for less than 1 percent of genotypes in total up to and including day 18. Wild75
type HIV accounted for most of the remaining 20 percent (Fig 1B).76
To examine whether the plateau in the frequency of mutant HIV was correlated with co-infection77
of the same cell with wild-type and mutant HIV, we single-cell sequenced HIV DNA by sorting GFP78
positive infected cells into wells of a multi-well plate at 1 cell per well, then lysing and amplifying79
the RT region followed by illumina sequencing. 60 cells were sequenced and analyzed for each time80
point, except for day 4 and day 12, where 30 cells were analyzed. At day 4, before selective pressure81
was applied, all infected cells showed wildtype HIV genomes (Fig 2). At day 10, there were 21 cells82
(35 percent) with EFV resistance mutations, consisting of 16 L100Imutations, 1 K103N mutation and83
4 G190A mutations. Interestingly, all mutations were co-expressed with wild type (Fig 2). The rest84
of the HIV DNA genomes were wild type only. In contrast, on day 18, where the mutant frequency85
stabilized at 80 percent, cells were infected by EFV resistant and wildtype HIV as follows: L100I (9086
percent), K103N (28 percent), and G190A (62 percent) and wildtype (5 percent) (Fig 2).87
Figure 2. Sequencing of viral genomes in single cells shows increasing frequency of co-infected cells with time.The relative frequencies of wild type and mutant HIV genomes per cell for the day 4, day 10, day 12 and day 18.Frequency is on the x-axis, cell number on y-axis. Cells were ranked by lowest to highest wild type frequency.Light grey is wild type virus, blue is the L100Imutant, green is K103N mutant and dark grey is G190A mutant.
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Figure 3. Co-transfection of wild type and mutant molecular clones yields resistant virus independent ofgenotype. (A) CFP expressing wild type and YFP expressing L100I EFV resistant mutant molecular clones wereeither transfected separately (left) or co-transfected (right) into a virus producer cell line. Shown are imagesafter producer line transfection, with CFP pseudo-coloured as red and YFP pseudo-coloured as green.Co-transfected cells which express both fluorescent proteins are yellow. (B) Sensitivity of cell-free virus collectedfrom the transfections to EFV. Sensitivity was measured as the transmission index (Tx), the ratio of the numberof infected cells in the presence of EFV divided by the number of infected cells in the absence of EFV. Left panelshows virus from separate transfections, while right panel shows virus from the co-transfection, with red andblue points mutant and wild type genotypes respectively. Error bars represent SD from two independentexperiments. For the left panel, the Tx values at 20nM EFV were significantly different for mutant and wildtype(p=0.05, two tailed t-test). The Tx values at 20nM EFV for mutant and wildtype in the right panel were notsignificantly different. (C) Predicted fraction of virions containing at least one mutant RT molecule as a functionof the ratio of genomic copies of drug sensitive versus resistant virus and the number of RT moleculespackaged. 4 of 10
Page 61 of Thesis
To directly test whether EFV resistant mutant HIV can complement wild type virus, we used88
transfection of molecular viral clones consisting of plasmids expressing a mutant and wild type89
virus in conjunction with a fluorescent protein. Upon transfection, molecular clones produce fully90
functional replicating virus which can be tested for resistance to EFV (Fig 3A). We transfected a91
molecular clone expressing CFP (Levy et al. (2004)) with a wild type genome into a virus producer92
cell line. The producer cells showed only CFP fluorescence (3A, left image). We next replaced the RT93
region of a YFP expressing HIV (Levy et al. (2004)) with the L100Imutant to create a molecular clone94
of the mutant. When we transfected this molecular clone into cells, the producer cell line showed95
YFP expression only (Fig 3A, middle image). We then co-transfected the molecular clones, which96
resulted in dual CFP and YFP expression from most fluorescent cells, indicating both viral strains97
being expressed from the same cell (Fig 3A, right image). We collected virus from each of the three98
conditions and used it to infect MT4 cells (see Fig S1 for gating strategy). Cells infected with virus99
made by single transfected cells were either sensitive (CFP expressing) or resistant (YFP expressing)100
to EFV (Fig 3B, left panel). In contrast, virus from the co-transfection showed resistance both for the101
wildtype CFP expressing genotype and YFP expressing mutant genotype (Fig 3B, right panel). For102
wildtype, resistance gained was comparable but slightly less relative to the YFP resistant mutant.103
However, the slight difference may be explained by incomplete co-transfection with both molecular104
clones (Fig 3A, right graph). This indicates that the wild type virus was able to complement with the105
mutant virus.106
To examine the expected effects of complementation of mutant and wild type HIV on the107
replication of each genotype, we constructed a computational model which considers the number108
of RT molecules packaged per virion and the ratio of wild type to mutant viral genomes (Fig 3C).109
The benefit to the wild type drug sensitive virus in complementation decreases at low numbers110
of RT molecules and higher number of wild type genomes, since in this case wild type virus does111
not package mutant RT. At the reported numbers of RT molecules per virion (roughly 50) (Panet112
and Kra-Oz (1978); Bauer and Temin (1980)) and ratios of wild type to mutant genomes of close to113
1, complementation of the wild type can be complete.114
Discussion115
We have observed that a quasispecies is formed in the face of EFV selective pressure, where116
wildtype HIV persists despite a fitness disadvantage. The fraction of drug sensitive HIV stabilized117
upon co-infection with EFV resistant virus in the same cell. Co-transfection of mutant and wildtype118
molecular clone in the same cell enabled the wild type to gain EFV phenotypic resistance. The119
necessary condition for complementation to occur in vivo is expression of multiple viral genotypes120
in the same cell. Multiple infections can occur by cell-to-cell spread, a directed mode of HIV121
transmission efficiently delivering HIV from the donor to target cell (Jolly et al. (2004); Sattentau122
(2008); Kinoshita et al. (1998); Sigal et al. (2011)). The frequency of HIV multiple infection per cell123
has been controversial, with some studies showing multiple infection per cell higher than expected124
by the Poisson distribution, hence supporting a directed process for viral transmission (Jung et al.125
(2002); Law et al. (2016)). Other studies did not show multiple infections at a frequency greater than126
that predicted by the Poisson distribution (Josefsson et al. (2011, 2013)). Clearly, the frequency of127
multiple infections per cell with different genotypes needs to be established before the effect of128
complementation in vivo can be quantified.129
Complementation interferes with selection and hence reduces fitness of the viral population by130
preventing the selection of more fit genotypes (Froissart et al. (2004)). There is evidence that the131
quasispecies stabilized by complementation is beneficial for the fitness of the population, since this132
allows deleterious variants to share components and result in a more functional virion, or keep a133
heterogeneous pool of virus which can react to rapid changes in the infection environment (Vignuzzi134
et al. (2006); Domingo et al. (2012); Lauring et al. (2013); Andino and Domingo (2015)). Interestingly,135
the majority mutant HIV in this study was coinfected with wildtype, despite non-saturating infection136
of the cell population. In contrast, most of wildtype infected cells had only the wildtype genotype.137
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This may indicate that wildtype infection may make the cells permissive for the L100Imutant; a138
benefit conferred by the quasispecies.139
The data here suggests that complementation could be important as a counter-force to drug140
resistant evolution. Inhibiting co-infection by interfering with mechanisms which cause co-infection,141
such as cell-to-cell spread, may therefore not only reduce infection in the face of ART and other142
forms of inhibition (Deeks et al. (2012); Hill et al. (2014)), but also limit viral diversity and hence the143
ability of HIV to evolve resistance.144
Methods and Materials145
Inhibitors, viruses and cell lines146
The antiretroviral EFV was obtained through the AIDS Research and Reference Reagent Program,147
National Institute of Allergy and Infectious Diseases, National Institutes of Health. RevCEM cells148
from Y. Wu and J. Marsh; MT-4 cells from D. Richman and HIV molecular clone pNL4-3 from M.149
Martin. The NL4-3YFP and NL4-3CFP molecular clones were gifts from D. Levy. Cell-free viruses150
were produced by transfection of HEK293 cells with pNL4-3 using TransIT-LT1 (Mirus) or Fugene151
HD (Roche) transfection reagents. Virus containing supernatant was harvested after two days152
of incubation and filtered through a 0.45µm filter (Corning). The number of virus genomes in153
viral stocks was determined using the RealTime HIV-1 viral load test (Abbott Diagnostics). The154
L100Imutant was evolved by serial passages of wild type NL4-3 in RevCEM cells in the presence155
of 20nM EFV. After 18 days of selection, the RT gene was cloned from the proviral DNA and the156
mutant RT gene was inserted into the NL4-3 molecular clone. RevCEM clone E7 used in this study157
were generated as previously described (Boullé, Müller et al. 2016). Briefly, the E7 clone was158
generated by subcloning RevCEM cells at single cell density. Surviving clones were subdivided into159
replicate plates. One of the plates was screened for the fraction of GFP expressing cells upon160
HIV infection using microscopy, and the clone with the highest fraction of GFP positive cells was161
selected. All cell lines not authenticated, and mycoplasma negative. Cell culture and experiments162
were performed in complete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate,163
HEPES, non-essential amino acids (Lonza), and 10 percent heat-inactivated FBS (Hyclone).164
Infection165
For a cell-free infection of RevCEM clones, 106 cells/ml were infected with 2X108 NL4-3 viral copies/ml166
(roughly 20ng p24 equivalent) for 2 days (day 0). For coculture infection, infected cells from the167
cell-free infection were used as the donors and cocultured with 106 cells/ml target cells (day 2).168
After two days of infection, two percent of the infected cells were added to uninfected targets and169
cocultured for a 2-day cycle (day 4). Thereafter, 2 percent of resuspended infected cells were added170
to uninfected targets in the presence of EFV and co-cultured for a 2-day cycle. This infection process171
was repeated every 2 days until day 18.172
Complementation infection173
To produce mixed CFP:YFP virus, NL4-3YFP and NL4-3CFP were added in equal concentrations (0.5174
ug/ul) to the Fugene HD (Roche) mixture for co-transfection into HEK293 cells. YFP and CFP virus175
was also produced separately, and added to a Fugene HD (Roche) at a concentration of 1ug/ul. For176
a cell-free infection of MT4 cells, 106 cells/ml were infected with 1x108 viral copies/ml with the177
following viral mixes: (1) co-transfected CFP:YFP virus; (2) a mix of CFP and YFP virus; (3) CFP virus;178
(4) YFP virus.179
Staining and flow cytometry180
The frequency of RevCEM E7 infected cells was detected by the amount of GFP positive cells on181
the FACSCaliber (BD Biosciences) machine using the 488 laser lines. The number of CFP and YFP182
positive cells in the MT4 infection was determined by the amount of CFP or YFP positive cells on the183
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FACAriaIII (BD Biosciences) using the 488nm laser line. Results were analysed with FlowJo 10.0.8184
software. For single cell sorting to detect the number of HIV DNA copies per cell, cells were single185
cell sorted using 85 micron nozzle in a FACSAriaIIImachine. GFP positive RevCEM clones were sorted186
into 96 well plates (Biorad) containing 30휇l lysis buffer (2.5휇l 0.1M Dithiothreitol, 5휇l 5 percent NP40187
and 22.5휇l molecular biology grade water (Kurimoto, Yabuta et al. 2007)).188
Microscopy189
For imaging infection by microscopy, cell density was reduced to 5X104 cells/ml and cells were190
attached to ploy-l-lysine (Sigma-Aldrich) coated optical six well plates (MatTek). Infections were191
imaged using a Metamorph-controlled Nikon TiE motorized microscope with a Yokogawa spinning192
disk with a 20x, 0.75 NA phase objective in a biosafety level 3 facility. Excitation sources were 488193
(GFP) and 445 (CFP) laser lines and emission was detected through a Semrock Brightline quad194
band 440-40 /521-21/607-34/700-45 nm filter. Images were captured using an 888 EMCCD camera195
(Andor). Images were analyzed using custom code developed with the Matlab Image Analysis196
Toolbox.197
Deep sequencing for detection of drug resistant mutants198
For single cells, the cells were lysed and DNA was kept suspended in the lysis buffer. For populations199
of cells, genomic DNA was extracted using the QIAamp DNA mini kit (Qiagen). Phusion hot start II200
DNA polymerase (New England Biolabs) PCR reaction mix (10휇l 5X Phusion HF buffer, 1휇l dNTPs,201
2.5휇l of the forward primer, 2.5휇l of the reverse primer, 0.5휇l Phusion hot start II DNA polymerase,202
2.5휇l of DMSO and molecular biology grade water to 50휇l reaction volume) was added to the lysed203
single cells or extracted genomic DNA of cell populations. Two rounds of PCR were performed.204
The first-round reaction amplified a region of the RT gene in the proviral DNA using the forward205
primer 5’ tcgtcggcagcgtcagatgtgtataagagacagTTAATAAGAGAACTCAAGATTTC 3’ and reverse primer 5’206
gtctcgtgggctcggagatgtgtataagagacagCCCCACCTCAACAGATGTTGTC 3’. The bold and italicised portion207
of the primers represents the Nextera® XT Index Kit adaptor. Cycling program was 98C for 30208
seconds, then 35 cycles of 98C for 10 seconds, 50C for 30 seconds and 72C for 15 seconds with a209
final extension of 72C for 5 minutes. 1휇l of the first round product was then transferred into a PCR210
mix as above, with second round Nextera XT Index Kit adaptor primers (forward 5’ tcgtcggcagcgtca-211
gatgtgtataagagacag 3’, reverse 5’ gtctcgtgggctcggagatgtgtataagagacag 3’). The second round PCR212
amplified a 400bp product which was then visualized on a 1 percent agarose gel. The PCR amplicon213
was gel extracted using the QIAquick gel extraction kit (Qiagen). Illumina indices were attached to214
the amplicon with the Nextera XT Index Kit and deep sequenced using the Illumina Miseq. Fast-q215
files were analysed in Geneious. Both 5’ and 3’ ends were trimmed with an error probability limit216
of 0.1. Drug resistant mutations were found based on a minimum variant frequency of 0.01 for217
populations of cells and 0.5 for single cells. The maximum variant P-value was 10−6.218
Model219
A stochastic simulation was performed to find the probability of a virus packaging at least one220
mutant RT molecule as a function of the total number of RT molecules packaged by one virus221
and the fraction of RT molecules in the cell produced by the mutant RT gene. A vector of random222
numbers with number of entries equal to the number of total RT molecules packaged was chosen223
using Matlab from a uniform distribution between 0 and 1. If at least one of the numbers was less224
than 1-Fwt, where Fwt is the wildtype frequency, the iteration was scored as containing at least one225
mutant RT. 104 iterations were performed for each combination of total RT molecules and Fwt, and226
the frequency of iterations with at least one mutant RT graphed.227
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Figure S1. Gating strategy to detect EFV sensitivity virus from singly infected and co-infected molecular clones.Virus was collected from producer cells singly transfected with wild type HIV expressing CFP or L100Imutant HIVexpressing YFP, or co-transfected with both molecular clones. MT4 cells were then infected with the virusderived from the co-transfection, or with the virus derived from the single transfections, where CFP and YFPexpressing virus was mixed 1:1 before the infection. The numbers of infected cells in quadrant Q1 and Q2 wasmeasured as the total number of cells infected with the CFP expressing virus, and Q2 and Q3 as the totalnumber of cells infected with YFP expressing virus. (A) Uninfected (left panel), CFP virus only (middle panel) orYFP virus only (right panel) controls. (B) Infection with virus from single transfections mixed 1:1. (C) Infectionfrom virus from the co-transfection. Efavirenz was added to each infection condition. The concentration ofEfavirenz added is indicated above each FACs plot.
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Abstract Measurement of the number of expressed viral genomes in in vivo infected individual9
cells requires new approaches involving high throughput detection of HIV transcript number and10
sequence per cell. Here we have tested the potential of several approaches for detecting and11
sequencing the transcriptional profiles of HIV infected cells.12
13
Introduction14
Multiple infections per cell impact: 1) degree of sensitivity of infection to drug (Sigal et al. (2011));15
2) survival of infected cells (Jackson et al. (2018)); 3) Timing of infection (Boullé et al. (2016); 4)16
Evolution of drug resistance and maintenance of a quasispecies (Jackson et al. (2018)). The clinical17
relevance of multiple infections per cell will depend on their frequency in in vivo infection. There is18
controversy over the frequency of cells which are multiply infected in vivo. One critical compartment19
where multiple infection could occur is lymph nodes/lymphoid tissue. Lymph nodes (LNs) may20
represent critical HIV reservoirs due to the high concentration of lymphocytes and the density of21
cellular interactions, which may make LN conducive to cell-to-cell spread (Jolly et al. (2004); Sigal22
et al. (2011); Sigal and Baltimore (2012)); and because limited drug penetration may make ongoing23
replication possible even in the presence of antiretroviral therapy (Fletcher et al. (2014); Lorenzo-24
Redondo et al. (2016)). Specific T cell subsets present in the LN have been reported to be central25
to the reservoir. These include CD3+CD4+PD1+CXCR5+ T follicular helper cells (Fukazawa et al.26
(2015); Banga et al. (2016)) and CD45RA-CCR7+CD27+ central memory T cells (Sallusto et al. (1999);27
Chomont et al. (2009)). However, the number of HIV infections per cell, and the viral sequences28
expressed by them, has not been characterized with high throughput approaches.29
Detection of expressed viral sequences in infected single cells requires detection of HIV tran-30
scripts. A novel approach to define the HIV cellular reservoir and associated sequences at the level31
of the single infected cell with high throughput is the emerging technology of single cell RNA-Seq.32
This enables analysis of single-cell transcriptomes to discover cell type/state (Paltiel et al. (2009)),33
and can potentially be used to detect HIV transcripts in individual cells. One such approach is34
Seq-Well (Gierahn et al. (2017)), a microwell-based platform containing roughly 86,000 subnanoliter35
wells pre-loaded with barcoded mRNA capture beads. In this approach, each cell is captured with36
a single bead in a single well using gravity. The wells are then sealed using a semi-permeable37
membrane, cells are lysed within the array, and cellular mRNAs are captured on barcoded beads.38
Reverse transcription, library preparation and paired-end sequencing are then carried out. Seq-Well39
enables transcriptomic profiling of thousands of cells in parallel, with each cell profiled individually40
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by applying unfixed cells in suspension to the microwell chip (Macosko et al. (2015)). It has been41
successfully applied to human tissue isolates including human lymph node biopsies, tumors, gut42
pinch biopsies, cerebrospinal fluid and other cellular sources (Gaublomme et al. (2015); Kimmerling43
et al. (2016); Tirosh et al. (2016)).44
In addition to Seq-Well, other single cell RNA-Seq approaches can be used to specifically detect45
and analyze the transcriptomes of HIV infected cells. These techniques sequence cells in a 96-well46
format and therefore would rely on enrichment strategies for HIV infected cells. One such approach47
is using Fixed and Recovered Intact Single-cell RNA (FRISCR) (Thomsen et al. (2016)). In this approach,48
HIV infected cells can be enriched using intracellular anti-HIV Gag (p24) single cell staining using a49
fluorescently labelled antibody. With FRISCR, the RNA content of the fixed, antibody labelled cells50
would be accessed by reversing the fixation. Fixed HIV infected cells would be single cell sorted,51
lysed, then de-crosslinked by heating. FRISCR has been successfully applied to radial glia cells of the52
human neocortex, yielding expression data similar to that of unfixed cells (Thomsen et al. (2016)).53
Another approach may be detection of HIV infected cells based on HIV envelope protein (Env)54
detection on the cell surface (Cohn et al. (2018)). This technique does not require fixation since ENV55
is not the cell surface, but is predicted to have a low signal to noise ratio based on the paucity of56
expressed Env (Zhu et al. (2006)) . If direct detection of HIV is not possible, an alternative is single57
cell RNA-Seq of cell types enriched for HIV infection. Here, cells are sorted based of cell-surface58
markers rather than fixing and using intracellular staining. These cell types are single cell sorted59
directly into a lysis buffer. As mentioned above, specific T cell subsets present in the LN, such as60
CD3+CD4+PD1+CXCR5+ T follicular helper cells, and CD45RA-CCR7+CD27+ central memory T cells61
have been reported to be central to the reservoir and these cell types may be frequently infected.62
To test feasibility of single cell RNA-Seq to detect HIV transcripts and sequences, we performed63
single cell RNA-Seq for the determination of infection frequency and the number of expressed64
HIV sequences per infected cell. This was applied to an in vitro infection. We also assessed65
the application of this approach to a cohort of LN from HIV infected study participants that we66
assembled.67
Single cell RNA-Seq detects multiple HIV sequences in in vitro infection68
We used an HIV in vitro infection of a cell line to test the feasibility of single cell RNA-Seq for69
detecting of multiple HIV sequences per cell. RevCEM cells (Wu et al. (2007)) are engineered to70
express GFP upon HIV Rev protein expression. Three different infections were setup with RevCEMs.71
We infected cells with: (1) HIV expressing wildtype reverse transcriptase (RT); (2) HIV harboring a72
single nucleotide RT mutant; (3) a co-infection of cells with wild type and mutant HIV. After two days73
of infection, we cell sorted at one cell per well based on GFP expression and used plate-based single74
cell RNA-Seq (Shalek et al. (2013); Patel et al. (2014)) to examine individual cells for viral transcripts75
(Figure 1). In these cells, we detected wild type HIV RT by single cell RNA-Seq when infection was76
with wild type virus, and mutant HIV RT when infection was with mutant virus. Importantly, we were77
able to detect both wild type and mutant transcripts in the same cell in co-infected cells (Figure78
1A). The approach allowed us to detect not only the sequences, but also the abundance of HIV79
transcripts per cell (Figure 1B). Therefore, our approach would enable us to rank the different HIV80
infected cell subsets by their quantitative contribution to the reservoir based on the number of HIV81
transcripts each cell produces.82
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Figure 1. Single-cell RNA-Seq strategy to identify HIV variants and number of transcripts per cell. (A) Reads fromthree representative cells infected with wild type HIV (left panel), the L100Imutant of the reverse transcriptase(RT) which confers EFV resistance (middle panel), or co-infected with wild type and mutant viruses (right panel).Each red rectangle represents HIV transcripts sequenced by single cell RNA-Seq from one cell. First nucleotide inboxed codon at the top is the mutation site. The wild type RT was detected in the wild type HIV infected cells,the mutant RT in the mutant infected cells, and both were detected in the cell co-infected with both variants. (B)Multiple individual cells were analysed from each infection condition for HIV transcript number. Each cell isrepresented by a horizontal bar, with bar length corresponding to the number of HIV transcripts expressed bythe cell at position 298 of the reverse Transcriptase (Pos 298). Bar colour represents the number of sequenceswhich were wildtype (blue) or mutant (yellow). Note that wild type transcripts were more common than mutanttranscripts in co-infected cells.
Single cell RNA-Seq applied to cells from LN83
We next tested whether Seq-Well is feasible for both transcriptional profiling cell types as well as84
the detection of HIV transcripts from lung LN cells. We applied the Seq-Well technique to a sorted85
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live population of lung LN cells of a participant from a cohort of resected lymph nodes from HIV86
infected individuals (Table 1 and 2). The main populations of cells from the LN we identified as87
T cells, B cells and antigen presenting cells (APCs, Figure 2A). In addition, we identified 30 cells88
expressing HIV transcripts in the T cell and APC populations (Figure 2B). The contribution of the89
cell subset to the reservoir may be determined by the number of viral transcripts produced by90
the cell. Important to note is that clinical parameters can skew the transcriptional profile of cells91
(Riou et al. (2016)). In the case of the LNs from the clinical cohort (described below), both history of92
multidrug resistant (MDR) or extremely drug resistant (XDR) TB may be confounding factors in the93
transcriptional profiles.94
Figure 2. Determining infected cell types in LNs from HIV positive patients by single cell RNA-Seq. (A) Completepreparation of single cells from a LN from an antiretroviral therapy (ART) treated individual (participant024-09-0198) was processed using Seq-Well. Single cell libraries were sequenced, and cells were clusteredaccording to their transcriptomes to obtain B cell, T cell and APC subsets. (B) HIV transcripts were detected incell subsets from (A).
Enrichment strategies95
With Seq-Well, only roughly 35 percent of the cells are recovered from loading the chip and only96
roughly 10 percent of the cells give readable depth and coverage of sequencing for analysis. Both97
the low frequency of HIV infected cells in the total population and the subsequent low yield in HIV98
transcriptomic data results in very few HIV infected cells being analyzed. There are two ways to99
increase the yield of HIV infected cells for analysis. Firstly, adapt the mRNA capture beads used in100
Seq-Well to prime from specific regions of HIV, secondly, to enrich on HIV infected cells. Enrichment101
can be done by: (1) Sorting directly on HIV positive cells using identification by either intracellular102
HIV Gag or surface HIV Env; (2) sorting on cell populations that have a higher frequency of HIV103
infection than other cell types.104
We first tested whether we could enrich for HIV based on cell type selection. To confirm whether105
cells were enriched for HIV infection or not, we used staining for intracellular HIV Gag. We found106
that the frequency of infected cells in the CD3+CD8-CD4+ subset from an HIV in vitro infection of107
Peripheral blood mononuclear cells (PBMCs) was 11.3 percent (Figure 3A). When compared to the108
frequency of infected cells in the total live population (Figure 3B), the CD3+CD8-CD4+ subset yielded109
a 3-fold enrichment for infected cells. This approach can be further refined by testing additional110
cell surface markers to obtain cell subsets with higher enrichment for HIV infection.111
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Figure 3. Enrichment of HIV infected cells by staining for cell subsets. p24 staining of PBMCs from an in vitroinfection with NL43-AD8. Infection was detected at the level of individual cells by staining with anti-HIV Gag(p24) antibody in the FITC channel. (A) Gating strategy for selecting live, CD3+CD8-CD4+p24+ cells. Live cellswere selected by exclusion of the death detection dye eFluor660. (B) The same infected PBMCs that as weregated in (A) without selection of the D3+CD8-CD4+ subset.
Assembly of a cohort of lymph nodes from HIV infected participants and112
detection of infected cells113
We assembled a cohort of LN from the field of surgery from individuals on suppressive ART114
undergoing indicated lung lobe resection in collaboration with clinicians at the Department of115
Cardiothoracic Surgery at Inkosi Albert Luthuli Central Hospital in Durban, South Africa. This cohort116
was assembled over a two-year period (2016-2018). Written informed consent was obtained in the117
home language for each participant (English or IsiZulu). The study protocol has been approved118
by the University of KwaZulu-Natal Institutional Review Board (approval BE024/09) and by the119
Institutional Biosafety Committee. In addition to LN, matched blood was obtained from each120
participant.121
Clinical parameters collected for each study participant included clinically diagnosed TB status122
(active TB highlighted in red in Table 1), gender, age, nadir CD4+ count, HIV diagnosis date, duration123
of infection before treatment, ART start date, and duration of ART before LN resection (Table 1). Out124
of the 24 study participants, 8 (33 percent) were clinically diagnosed with active TB. There were 13125
female participants (54 percent). Most active TB cases were in males (5/8, 62 percent). Time before126
ART initiation was variable and ranged from less than 1 year to 6 years. Time on ART ranged from127
less than 1 year to 13 years. The active TB group was enriched with individuals with a history of128
MDR or XDR TB, with 4 out of 6 MDR/XDR cases.129
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Table 1. Clinical parameters of LN cohort
Entries in red indicate participants with clinical diagnosis of active TB. PID, participant identification.
To determine ART status, antiretroviral drug (ARV) levels of efavirenz (EFV), emtricitabine (FTC),130
tenofovir (TDF), ritonavir (RTV), lopinavir (LPV), and abacavir (ABC) were measured in-house by liquid131
chromatography coupled with tandem mass spectrometry (LC/MS/MS). Viral load was measured132
using the Abbott RealTime HIV-1 Viral Load Assay, with a limit of detection of 40 copies/ml (Table133
2). Interestingly, in the active TB group, 4/8 (50 percent) of participants showed low level viremia134
(LLV), compared to 2/16 (12 percent) in the TB cured group This difference was significant (p=0.02135
by bootstrap).136
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Table 2: Measured parameters of LN cohort
All ARV in ng/ml in plasma. Entries in red indicate participants with a clinical diagnosis of active TB. Entries in blue indicate participants
with no viral suppression. PID, participant identification number. BLQ, below level of quantitation. N/A, Not available. Pend, pending.
In order to use single cell RNA-Seq approaches with the LNs described above, we first needed to137
test whether the LN cells harbored HIV. We tested LNs for HIV DNA copies, a measure of the HIV138
reservoir (Chun et al. (1997); Eriksson et al. (2013); Laird et al. (2013)). We stained LN cells from139
HIV positive participants for host surface markers and sorted non-activated CD3+CD4+ T cells from140
LN (Figure 4A) into 96-well plates at 10 cells per well and determined the frequency of infection.141
We performed PCR to a conserved region of the HIV-1 reverse transcriptase gene (Figure 4B). We142
detected a DNA copy frequency of 0.8 percent, within range for HIV DNA frequency observed for143
CD4+ T cells of rectal origin in ART suppressed individuals (Eriksson et al. (2013)).144
To examine HIV protein expression in LN, we used anti-p24 single-cell staining to detect HIV145
Gag after 12 hour activation with phytohemagglutinin (PHA) and IL-2. The short activation time146
should reflect in vivo infection without additional cycles in vitro (Boullé et al. (2016)). Four LN147
were analyzed from three ART suppressed participants. LN cells from an HIV negative individual148
infected or uninfected in vitro were used as positive and negative controls, respectively (Figure149
4C). p24-positive cell frequency in ART suppressed participants ranged from 0.01 percent to 0.07150
percent, with different LNs from the same individual showing a similar percentage of infected cells.151
Frequencies were an order of magnitude lower than reported for HIV DNA positive CD4+ cells from152
rectal biopsy samples (Eriksson et al. (2013)) and our measurement of HIV DNA frequency. This153
may indicate that only a subset of cells with HIV DNA produce HIV proteins .154
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Discussion155
Here, we have shown that single cell RNA-seq is a technique that can be used to determine the156
frequency of infection, the number of HIV infections per cell, as well as cell types in in vivo infected157
lymph nodes. Additionally, our ability to elucidate the viral sequence can be used to identify158
resistance mutations which may result in ongoing replication by ARV resistant HIV. This could also159
allow us to sequence and clone out the ENV protein and test tropism in relation to the cell subset160
the virus was detected in.161
Further improvement to determining the frequency of infection would require calibration of162
optimal protocols for enrichment of infected cells based on detection of HIV infection, or enrichment163
for infected cell types. This would enable us to quantitatively detect with high throughput HIV164
expression in individual cells, and importantly, determine the frequency of cells which express165
more than one HIV sequence. Furthermore, standard mRNA priming from polyA may not result in166
sufficient HIV genome coverage, leading to gaps in the coverage of all viral variants in the cells. To167
circumvent this problem, in future work we will engineer the Seq-Well capture beads to bind HIV168
specific mRNA at different locations on the HIV genome (Macosko et al. (2015)). This should yield169
greater coverage of the HIV genome and thus allow us to better quantify the number of different170
HIV sequences that occur per infected cell.171
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GENERAL DISCUSSION 1 
Host cell survival and adaptability of HIV during therapy are pre-requisites to long-term 2 
persistence. This in turn means that HIV needs to: (1) strike a delicate balance between virulence 3 
and survival in its host to be optimally infectious; (2) evolve and maintain genetic diversity in order 4 
to adapt to selective pressures. In this thesis I show that when cells become multiply infected with 5 
HIV, through a mode of infection such as cell-to-cell spread, partially reducing infection with 6 
inhibitors results in: (1) increased number of live infected cells (2) the evolution of a quasispecies 7 
which is maintained through complementation. Furthermore, I show that single cell RNA-Seq 8 
methods are feasible to quantify multiple infections per cell from in vivo HIV infected lymph node 9 
cells.  10 
 11 
In Chapter 2, I demonstrated that when cells are infected and die in a probabilistic way, there are 12 
two possible outcomes of partially inhibiting infection. In the case where cells are infected by 13 
single infection attempts, inhibition always leads to a decline in the number of live infected cells, 14 
since inhibition reduces the number of infections per cell from one to zero. In contrast, in the case 15 
of multiple infection attempts per cell, the possibility exists that inhibition reduces the number of 16 
integrating HIV DNA copies without extinguishing infection of the cell completely. If each HIV DNA 17 
copy increases the probability of cell death, reducing the number of HIV DNA copies without 18 
eliminating infection would lead to an increased probability of infected cell survival. In turn, this 19 
would lead to an increase in the number of live infected cells. In both a cell line and lymph node 20 
cells, I observed an increase in the number of live infected cells. This correlated to fewer viral 21 
DNA copies per cell. Further increasing inhibitor concentration led to a decline in live infected cell 22 
numbers, and infecting with EFV resistant mutants shifted the peak in live infected number to 23 
higher EFV concentrations. The work here reinforces previous findings that successful completion 24 
of reverse transcription and infection leads to cellular cytotoxicity and in addition measures for the 25 
first time the probability of infection and cell death per copy of HIV DNA. This work supports recent 26 
findings that ARVs promote persistent infection by increasing the half-life of latently infected cells 27 
in HIV reservoirs, since a live cell is the prerequisite of a latently infected one 1. 28 
 29 
In Chapter 3, I showed that during evolution in the face of drug, drug sensitive HIV can be 30 
maintained in the quasispecies despite a fitness disadvantage. I demonstrated that the fraction of 31 
drug sensitive HIV stabilized upon co-infection with an EFV resistant HIV mutant. Co-transfection 32 
of a mutant and wildtype molecular clone proved this in a controlled experiment. Complementation 33 
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may interfere with selection and hence reduce fitness of the viral population by preventing the 34 
selection of more fit genotypes 2. However, there is evidence that the quasispecies allows the 35 
infection to keep a heterogeneous pool of virus which is more able to react to rapid changes in 36 
the infection environment, hence greatly enhancing the ability of infection to rapidly adapt to 37 
selective pressure 3-6. 38 
 39 
The necessary condition for both a peak in the number of live cells in the face of partial inhibition 40 
and complementation to occur in vivo is expression of multiple viral copies in the same cell. The 41 
presence of multiple infections of the same cell has been controversial, with some studies 42 
showing multiple infections per cell 7,8 whilst other studies did not show multiple infections at a 43 
frequency greater than that predicted by the Poisson distribution 9,10. In Chapter 4, I showed that 44 
single cell RNA-Seq methods can be used to determine whether lymph node cells are multiply 45 
infected. Enrichment strategies are necessity for some of the single cell RNA-Seq techniques 46 
given the current limitations on depth of coverage in the sequencing. Given that certain cell types 47 
such as CD3+CD4+PD1+CXCR5+ T follicular helper cells 11,12 and CD45RA-CCR7+CD27+ 48 
central memory T cells 13,14 have been reported to be central to the reservoir in lymph nodes , it 49 
should be possible to enrich for these groups as the next step.  50 
 51 
In both Chapter 2 and 3, the main antiretroviral used was EFV, a common component of first line 52 
therapy which is vulnerable to drug resistant mutations. An infection optimum should occur with 53 
other classes of antiretrovirals, since all drugs should decrease the multiplicity of infection 54 
between cells. Complementation may be possible with other antiretrovirals such as integrase or 55 
protease inhibitors. Like reverse transcriptase, there is no known mechanism which prevents one 56 
HIV strain packaging integrase or protease from another HIV strain if both strains are in the same 57 
cell. The number of these molecules packaged into one virion and how many molecules are 58 
needed to perform their function are other factors which would determine whether phenotypic 59 
mixing or complementation of integrase or protease is enough to maintain the quasispecies.  60 
 61 
Taken together, the results in this thesis show that under sub-optimal inhibition, HIV can become 62 
optimally infectious and generate a quasispecies. These features are necessary for HIV to survive 63 
and as described in this thesis, are possible when cells become multiply infected. Furthermore, I 64 
demonstrated that single cell RNA-Seq methods are feasible for validating whether cells from in 65 
vivo infected lymph nodes are multiply infected. Results from Chapter 2 and 3 may have important 66 
implications in the establishment of reservoirs in the context of poorly controlled infections, 67 
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infections with some degree of drug resistance or infections where some replication takes place 68 
in the face of ARVs. Currently, proposed approaches to eliminate non-replicating reservoirs - 69 
where cells are latently infected with HIV - is to purge these cells by activating HIV production 70 
with HDAC inhibitors 15-18. This strategy may not successfully eliminate HIV because latently 71 
infected cells may contain few functional HIV proviral copies, and therefore these cells would not 72 
die when reactivated – as the probability of infection with a single virion is low. The results in this 73 
thesis may also suggest that inhibiting cell-to-cell spread, may not only reduce infection in the 74 
face of ARVs and other forms of inhibitors, but limit viral diversity and the ability of HIV to evolve 75 
resistance. 76 
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